var title_f26_33_27152="Reduce lower limb fatigue standing";
var content_f26_33_27152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56903&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reduce lower limb fatigue while standing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 449px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    If the patient's job or task requires prolonged standing at one site, placing a 12-inch long 2x4 inch board on the floor, then placing one foot on and off of it at intervals, alternating feet, can reduce lower limb fatigue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sharon Alzner, MPT.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_33_27152=[""].join("\n");
var outline_f26_33_27152=null;
var title_f26_33_27153="Severe fetal hydronephrosis";
var content_f26_33_27153=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe bilateral fetal hydronephrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial view of the fetal abdomen demonstrating spine and two kidneys with hydronephrosis in a second trimester fetus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_33_27153=[""].join("\n");
var outline_f26_33_27153=null;
var title_f26_33_27154="Pelvic lateral compression fracture type II";
var content_f26_33_27154=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pelvic lateral compression fracture: Type II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 511px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Type II lateral compression fracture with left sided rami and sacral fractures. B) CT scan illustrating the classic crescent fracture pattern.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jim Fiechtl, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_33_27154=[""].join("\n");
var outline_f26_33_27154=null;
var title_f26_33_27155="Vaginal birth after cesarean delivery (VBAC)";
var content_f26_33_27155=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Vaginal birth after cesarean delivery (VBAC) (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/33/27155/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27155/contributors\">",
"     F Gary Cunningham, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27155/contributors\">",
"     C Edward Wells, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/33/27155/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27155/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/33/27155/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27155/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/33/27155/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For much of the 20",
"    <sup>",
"     th",
"    </sup>",
"    century, most people believed that a woman who had previously undergone a cesarean delivery (previously termed a C-section) would require a repeat cesarean delivery for future pregnancies. From studies done after 1960, we learned that the dictum &ldquo;once a cesarean, always cesarean&rdquo; no longer applies. It appears that many women who have previously undergone cesarean delivery can safely attempt a trial of labor to have a vaginal delivery in subsequent pregnancies.",
"   </p>",
"   <p>",
"    The following are important definitions regarding vaginal birth after cesarean (VBAC) delivery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial of labor after cesarean (TOLAC) is a planned attempt to labor by a woman who has previously undergone a cesarean delivery and desires a subsequent vaginal delivery.",
"     </li>",
"     <li>",
"      A VBAC is a &ldquo;successful&rdquo; trial of labor resulting in a vaginal birth.",
"     </li>",
"     <li>",
"      A TOLAC may result in either a &ldquo;successful&rdquo; VBAC or a &ldquo;failed&rdquo; trial of labor resulting in a repeat cesarean delivery.",
"     </li>",
"     <li>",
"      A repeat cesarean delivery (RCD) may be planned and scheduled beforehand and thus is an elective repeat cesarean delivery (ERCD). If the woman who plans an ERCD enters spontaneous labor before the scheduled date, this is still considered an ERCD even if delivery is unscheduled. The woman with a failed TOLAC undergoes a RCD that is unplanned and unscheduled.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BENEFITS OF VAGINAL BIRTH AFTER CESAREAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of a trial of labor after cesarean (TOLAC) resulting in a vaginal birth after cesarean (VBAC) include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shorter length of hospital stay and postpartum recovery (in most cases)",
"     </li>",
"     <li>",
"      Fewer complications, such as postpartum fever, wound or uterine infection, thromboembolism (blood clots in the leg or lung), need for blood transfusion",
"     </li>",
"     <li>",
"      Fewer neonatal breathing problems",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISKS OF VAGINAL BIRTH AFTER CESAREAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks of an attempted VBAC or TOLAC include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk of failed trial of labor after cesarean (TOLAC) without a vaginal birth after cesarean (VBAC) resulting in repeat cesarean delivery (RCD) in about 20 to 40 percent of women who attempt VBAC.",
"     </li>",
"     <li>",
"      Risk of rupture of uterus resulting in an emergency cesarean delivery. The risk of uterine rupture may be related in part to the type of uterine incision made during the first cesarean delivery. A previous transverse uterine incision has the lowest risk of rupture (0.2 to 1.5 percent risk). Vertical or T-shaped uterine incisions have a higher risk of uterine rupture (4 to 9 percent risk) [1]. It is important to remember that the direction of the skin incision does not indicate the type or direction of the uterine incision; a woman with a transversal (bikini) skin incision may have a vertical uterine incision.",
"     </li>",
"     <li>",
"      While women who attempt TOLAC and VBAC have a low risk of uterine rupture, the risk of uterine rupture is higher with VBAC than with RCD. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"       \"Patient information: C-section (cesarean delivery) (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of fetal death is very low with both VBAC and elective repeat cesarean delivery (ERCD), but the likelihood of fetal death is higher with VBAC than with ERCD. Maternal death is very rare with either type of delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     WHO SHOULD CONSIDER A TOLAC AND VBAC?",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both the American College of Obstetricians and Gynecologists (ACOG) and the National Institutes of Health (NIH) suggest that a trial of labor after cesarean (TOLAC) to attempt a vaginal birth after cesarean (VBAC) is an acceptable option for a woman who has undergone one prior cesarean delivery with a low transverse uterine incision, assuming there are no other conditions that would normally require a cesarean delivery (as an example, placenta previa) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/33/27155/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ACOG further suggests that a woman with two prior low transverse uterine incisions, or a woman with a twin pregnancy, or a woman who requires induction of labor may also be considered candidates for VBAC with appropriate counseling [",
"      <a class=\"abstract\" href=\"UTD.htm?26/33/27155/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TOLAC with anticipated VBAC should be attempted only in those facilities capable of performing emergency cesarean deliveries and, thus, those with an appropriate nursing staff, anesthesia team, operating room, and obstetrician or other surgeon immediately available in case an emergency cesarean delivery becomes necessary.",
"     </li>",
"     <li>",
"      A woman considering VBAC should discuss with her health-care provider the risks and benefits of VBAC versus an elective repeat cesarean delivery (ERCD) and the discussion should include plans for intervention in case of uterine rupture or another indication for an emergency cesarean delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Management during labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many ways, a woman who attempts VBAC is managed similarly to other women anticipating a vaginal delivery. A fetal monitor may be used to observe the baby's heart rate and monitor for early signs of fetal distress. Medications to induce labor or improve contractions (eg, oxytocin [Pitocin]) are used cautiously since they can increase the risk of uterine rupture. If problems occur during labor, a cesarean delivery will likely be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     VBAC SUCCESS RATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, 60 to 80 percent of women who are considered candidates for a trial of labor after cesarean (TOLAC) to attempt vaginal birth after cesarean (VBAC) will have a successful vaginal birth (VBAC) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27155/abstract/3\">",
"     3",
"    </a>",
"    ]. Factors that increase the chances for a successful VBAC in an individual woman include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A previous vaginal delivery, especially a previous VBAC",
"     </li>",
"     <li>",
"      Spontaneous onset of labor (labor is not induced)",
"     </li>",
"     <li>",
"      Normal progress of labor, including dilation and effacement (thinning) of the cervix",
"     </li>",
"     <li>",
"      Prior cesarean delivery performed because the baby's position was abnormal (breech)",
"     </li>",
"     <li>",
"      Only one prior cesarean delivery",
"     </li>",
"     <li>",
"      The prior cesarean delivery was performed early in labor, and not after full cervical dilatation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2287264921\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11566367\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=see_link\">",
"     Patient information: C-section (cesarean delivery) (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?19/60/20418?source=see_link\">",
"     Patient information: Vaginal birth after cesarean delivery (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11566392\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"     Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=see_link\">",
"     Choosing the route of delivery after cesarean birth",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37862?source=see_link\">",
"     Repeat cesarean delivery",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28535?source=see_link\">",
"     Cervical ripening and induction of labor in women with a prior cesarean delivery",
"    </a>",
"    <br/>",
"    <br/>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"       The National Library of Medicine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.mayoclinic.com/\">",
"       The Mayo Clinic",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27155/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27155/abstract/1\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice bulletin no. 115: Vaginal birth after previous cesarean delivery. Obstet Gynecol 2010; 116:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27155/abstract/2\">",
"      National Institutes of Health. National Institutes of Health Consensus Development Conference Statement vaginal birth after cesarean: new insights March 8-10, 2010. Semin Perinatol 2010; 34:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27155/abstract/3\">",
"      Mozurkewich EL, Hutton EK. Elective repeat cesarean delivery versus trial of labor: a meta-analysis of the literature from 1989 to 1999. Am J Obstet Gynecol 2000; 183:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27155/abstract/4\">",
"      Macones GA, Peipert J, Nelson DB, et al. Maternal complications with vaginal birth after cesarean delivery: a multicenter study. Am J Obstet Gynecol 2005; 193:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27155/abstract/5\">",
"      ACOG Practice Bulletin #54: vaginal birth after previous cesarean. Obstet Gynecol 2004; 104:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27155/abstract/6\">",
"      Montgomery AA, Emmett CL, Fahey T, et al. Two decision aids for mode of delivery among women with previous caesarean section: randomised controlled trial. BMJ 2007; 334:1305.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6727 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-93.125.6.160-7DBF348CA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_33_27155=[""].join("\n");
var outline_f26_33_27155=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BENEFITS OF VAGINAL BIRTH AFTER CESAREAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISKS OF VAGINAL BIRTH AFTER CESAREAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      WHO SHOULD CONSIDER A TOLAC AND VBAC?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Management during labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      VBAC SUCCESS RATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2287264921\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11566367\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11566392\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28535?source=related_link\">",
"      Cervical ripening and induction of labor in women with a prior cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=related_link\">",
"      Choosing the route of delivery after cesarean birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/60/20418?source=related_link\">",
"      Patient information: Vaginal birth after cesarean delivery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37862?source=related_link\">",
"      Repeat cesarean delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_33_27156="UPJ obstruction schematic drawing";
var content_f26_33_27156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Ureteropelvic junction obstruction (UPJ)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 558px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic diagram of ureteropelvic obstruction that demonstrates the location of a functional or anatomical abnormality resulting in renal pelvic dilatation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baskin LS, Kogan BA. Handbook of Pediatric Urology, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_33_27156=[""].join("\n");
var outline_f26_33_27156=null;
var title_f26_33_27157="Precut sphincterotomy: Another perspective on efficacy and complications";
var content_f26_33_27157=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Precut sphincterotomy: Another perspective on efficacy and complications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/33/27157/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27157/contributors\">",
"     David J Desilets, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27157/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/33/27157/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27157/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/33/27157/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27157/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/33/27157/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precut sphincterotomy refers to a variety of endoscopic techniques used to gain access to the bile duct and rarely the pancreatic duct during endoscopic retrograde cholangiopancreatography before deep cannulation has been achieved. The term \"precut\" has been used to describe this technique because an incision is made on the papilla prior to free cannulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    wire guidance. Most experts feel that precut sphincterotomy is risky, and that it is a technique which should be performed by experts only [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This topic review will briefly discuss the efficacy of precut sphincterotomy while focusing on the risks and complications. A discussion of the technique is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/5/7254?source=see_link\">",
"     \"Precut sphincterotomy: Another perspective on indications and techniques\"",
"    </a>",
"    .) Because of the controversy surrounding this area, this topic is also presented separately from the perspective of another authority. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/10/25767?source=see_link\">",
"     \"Precut (access) papillotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases precut sphincterotomy is a method of last resort, to be used when all other attempts at cannulation during endoscopic retrograde cholangiopancreatography (ERCP) with standard cannulas, tapered cannulas, papillotomes, and guidewires have failed. There is ample support in the literature to show that precut sphincterotomy is effective at gaining biliary access. Numerous reports have demonstrated success rates of 65 to 100 percent, either in the first or subsequent attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. There is also little doubt that these published series represent the experience of the world's experts; relatively inexperienced endoscopists who rarely use precut techniques are unlikely to publish their data. The true cannulation rate among community gastroenterologists after attempted needle-knife papillotomy or other type of precut will probably never be known.",
"   </p>",
"   <p>",
"    No one disputes the efficacy of precut sphincterotomy at improving the success rate in what would otherwise be failed ERCPs, but at what cost [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/7\">",
"     7",
"    </a>",
"    ]? It is widely held that precut papillotomy raises the complication rate, at least compared with diagnostic ERCP alone, and probably compared with conventional sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/2,8-14\">",
"     2,8-14",
"    </a>",
"    ]. This controversial topic will be explored below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of precut sphincterotomy are the same as those encountered with conventional sphincterotomy, namely bleeding, perforation, pancreatitis, and cholangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/15\">",
"     15",
"    </a>",
"    ]. Other complications related to the procedure (respiratory arrest, myocardial infarction, stroke, aspiration, etc), but which do not result directly from sphincterotomy, are discussed elsewhere and will not be addressed here [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/16\">",
"     16",
"    </a>",
"    ]. The crux of the matter is whether these sphincterotomy-related complications occur with increased frequency after precutting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=see_link\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There appear to be two camps involved in this debate, and both have data to support their views. There are some who feel that precutting techniques are inherently more dangerous than standard sphincterotomy, and should thus be left to the experts. Informal surveys of community gastroenterologists have demonstrated that only a few ever use precutting; even some experts avoid the needle-knife entirely, while many use it as sparingly as possible. On the other hand, there are a number of authors who have concluded that precutting is effective and safe [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/5,17-23\">",
"     5,17-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Post-precut complication rates vary widely in the literature, from as low as 2.6 percent to as high as 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/14,17,23,24\">",
"     14,17,23,24",
"    </a>",
"    ]. Analysis of risk factors that apply specifically to precut sphincterotomy is difficult because most of the published series have either a low number of precuts (compared with standard sphincterotomy), a very low complication rate, or both. As a general rule, risk factors for complications after precutting are felt to be the same as those of conventional sphincterotomy, namely small duct size, suspected sphincter of Oddi dysfunction (SOD), ampullary tumor, malignant obstructive jaundice, coagulopathy, inexperience of the",
"    <span class=\"nowrap\">",
"     operator/small",
"    </span>",
"    center, difficulty with cannulation, younger patients, and possibly periampullary diverticula [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/8,11,12,15,25\">",
"     8,11,12,15,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With careful review of the literature, two facts emerge:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Centers that do the most precuts seem to have the lowest complication rates.",
"     </li>",
"     <li>",
"      There appears to be no substitute for experience. As an example, many centers in northern Europe, and a few in the United States and Britain tend to precut early and often (&gt;10 percent of the time) rather than traumatize the papilla with repeated attempts at cannulation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/18,21,26,27\">",
"       18,21,26,27",
"      </a>",
"      ]. Precut rates as high as 42 percent have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/22\">",
"       22",
"      </a>",
"      ]. The complications rates in these centers are rather low, ranging from 2.6 to 12 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are two explanations for this seeming contradiction. First, centers where precutting is frequent generate endoscopists with a high degree of skill at precut papillotomy. Second, early decision to precut may protect the papilla from the trauma of repeated attempts at conventional cannulation, paradoxically lowering the complication rate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/4,28\">",
"     4,28",
"    </a>",
"    ], or at least not increasing it [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/29\">",
"     29",
"    </a>",
"    ]. That is, precut papillotomy may have been given a bad name because it is usually not attempted until after the papilla has been bloodied by numerous fruitless attempts at cannulation. Late decision to use the needle-knife preselects a population of patients in whom the damage may already be done [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/30\">",
"     30",
"    </a>",
"    ]. It may be that earlier reversion to the needle knife is safer in the long run, assuming adequate training and familiarity with precut techniques. Precutting is not a substitute for skill at biliary cannulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SPHINCTER OF ODDI DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, no risk factor specific to precut papillotomy has been clearly identified because studies have been small",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    complication rates are low. However, risks for complication in precutting are generally felt to be the same as those in conventional sphincterotomy.",
"   </p>",
"   <p>",
"    One of these risk factors has been singled out as being particularly hazardous for standard sphincterotomy: suspected sphincter of Oddi dysfunction (SOD). This is especially true in the setting of small or normal-sized bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/8,11,25,31\">",
"     8,11,25,31",
"    </a>",
"    ]. One would therefore expect a higher rate of precut complications in patients with SOD. As a result, some authorities specifically admonish against use of the needle-knife in patients in whom SOD is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, this hypothesis was not supported in a study involving 423 patients undergoing sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/25\">",
"     25",
"    </a>",
"    ]. Although conventional sphincterotomy was associated with more complications in patients with SOD than for other indications (10.8 versus 4.3 percent), the complication rate after precut in SOD was surprisingly lower than that of standard sphincterotomy (8.6 versus 11.5 percent).",
"   </p>",
"   <p>",
"    On the other hand, different results were observed in another series in which the overall complication rate was 24 percent after precuts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/8\">",
"     8",
"    </a>",
"    ]. When done for suspected SOD, the pancreatitis rate alone increased to 35 percent. Furthermore, the frequency of severe complications was substantially higher when precuts were performed for SOD compared with other indications (24 versus 2 percent). Apparently, the jury is still out concerning precut sphincterotomy for SOD.",
"   </p>",
"   <p>",
"    Our own data support early precut sphincterotomy for SOD. From January 1991 to October 1997, we identified 100 consecutive cases of Type II SOD treated with endoscopic biliary sphincterotomies at our institution, with 26 of these being initiated as with needle-knife precut (26 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/32\">",
"     32",
"    </a>",
"    ]. In the same period, there were 1,172 biliary sphincterotomies for all other indications, with about 15 percent of these being initiated as needle-knife precuts. The overall complication rate of the SOD group (comprising two cases of pancreatitis) was not significantly different than that of the \"all others\" group (2 versus 1 percent) in whom there were seven patients with pancreatitis, two with bleeding, and two with perforations. The slightly increased pancreatitis rate in the SOD group was actually expected to be higher based upon previously published reports [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/8,25\">",
"     8,25",
"    </a>",
"    ]. We believe that the decision to precut early in this very risky group reduced the expected increase in complications by avoiding numerous failed cannulation attempts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COMPARISON OF TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data in which different precutting methods at the same institution have been directly compared. One such report included 103 patients with choledocholithiasis who were randomly assigned to needle-knife precut beginning at the ampullary orifice or so-called \"fistulotomy\" beginning at an arbitrary point above the orifice [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27157/abstract/33\">",
"     33",
"    </a>",
"    ]. Both methods were equally successful at achieving selective biliary cannulation, but stone extraction was significantly more successful with the traditional needle-knife precut method (98 versus 83 percent). However, the needle-knife precut method was more often associated with hyperamylasemia (18 versus 3 percent) and clinical pancreatitis (8 versus 0 percent). All other complications (bleeding, perforation, cholangitis, and death) were equal in the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83651580\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Precut sphincterotomy refers to a variety of endoscopic techniques used to gain access to the bile duct and rarely the pancreatic duct during endoscopic retrograde cholangiopancreatography before deep cannulation has been achieved. The term \"precut\" has been used to describe this technique because an incision is made on the papilla prior to free cannulation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      wire guidance. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases precut sphincterotomy is a method of last resort, to be used when all other attempts at cannulation during endoscopic retrograde cholangiopancreatography (ERCP) with standard cannulas, tapered cannulas, papillotomes, and guidewires have failed. Success rates of 65 to 100 percent have been reported for precut sphincterotomy performed by endoscopists experienced in the procedure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of precut sphincterotomy are the same as those encountered with conventional sphincterotomy, namely bleeding, perforation, pancreatitis, and cholangitis, and they are related to endoscopist experience. Whether complications are more common with precut sphincterotomy compared with conventional sphincterotomy is unsettled. Reported complication rates range from 2.6 percent to as high as 20 percent. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/1\">",
"      Cotton PB. Precut papillotomy--a risky technique for experts only. Gastrointest Endosc 1989; 35:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/2\">",
"      Conio M, Saccomanno S, Aste H, Pugliese V. Precut papillotomy: primum non nocere. Gastrointest Endosc 1990; 36:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/3\">",
"      Dhir V, Swaroop VS, Mohandas KM, et al. Precut papillotomy using a needle knife: experience in 100 patients with malignant obstructive jaundice. Indian J Gastroenterol 1997; 16:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/4\">",
"      Rollhauser C, Johnson M, Al-Kawas FH. Needle-knife papillotomy: a helpful and safe adjunct to endoscopic retrograde cholangiopancreatography in a selected population. Endoscopy 1998; 30:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/5\">",
"      Rabenstein T, Ruppert T, Schneider HT, et al. Benefits and risks of needle-knife papillotomy. Gastrointest Endosc 1997; 46:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/6\">",
"      de Weerth A, Seitz U, Zhong Y, et al. Primary precutting versus conventional over-the-wire sphincterotomy for bile duct access: a prospective randomized study. Endoscopy 2006; 38:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/7\">",
"      Baillie J. Needle-knife papillotomy revisited. Gastrointest Endosc 1997; 46:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/8\">",
"      Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/9\">",
"      Cotton PB. Needleknife precut sphincterotomy: the devil is in the indications. Endoscopy 1997; 29:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/10\">",
"      Booth FV, Doerr RJ, Khalafi RS, et al. Surgical management of complications of endoscopic sphincterotomy with precut papillotomy. Am J Surg 1990; 159:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/11\">",
"      Boender J, Nix GA, de Ridder MA, et al. Endoscopic papillotomy for common bile duct stones: factors influencing the complication rate. Endoscopy 1994; 26:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/12\">",
"      Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/13\">",
"      Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/14\">",
"      Kahaleh M, Tokar J, Mullick T, et al. Prospective evaluation of pancreatic sphincterotomy as a precut technique for biliary cannulation. Clin Gastroenterol Hepatol 2004; 2:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/15\">",
"      Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/16\">",
"      Hart R, Classen M. Complications of diagnostic gastrointestinal endoscopy. Endoscopy 1990; 22:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/17\">",
"      Leung JW, Banez VP, Chung SC. Precut (needle knife) papillotomy for impacted common bile duct stone at the ampulla. Am J Gastroenterol 1990; 85:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/18\">",
"      Foutch PG. A prospective assessment of results for needle-knife papillotomy and standard endoscopic sphincterotomy. Gastrointest Endosc 1995; 41:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/19\">",
"      Goff JS. Common bile duct pre-cut sphincterotomy: transpancreatic sphincter approach. Gastrointest Endosc 1995; 41:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/20\">",
"      Bruins Slot W, Schoeman MN, Disario JA, et al. Needle-knife sphincterotomy as a precut procedure: a retrospective evaluation of efficacy and complications. Endoscopy 1996; 28:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/21\">",
"      Gholson CF, Favrot D. Needle knife papillotomy in a university referral practice. Safety and efficacy of a modified technique. J Clin Gastroenterol 1996; 23:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/22\">",
"      Rabenstein T, Schneider HT, Hahn EG, Ell C. 25 years of endoscopic sphincterotomy in Erlangen: assessment of the experience in 3498 patients. Endoscopy 1998; 30:A194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/23\">",
"      Swan MP, Alexander S, Moss A, et al. Needle knife sphincterotomy does not increase the risk of pancreatitis in patients with difficult biliary cannulation. Clin Gastroenterol Hepatol 2013; 11:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/24\">",
"      Huibregtse K, Katon RM, Tytgat GN. Precut papillotomy via fine-needle knife papillotome: a safe and effective technique. Gastrointest Endosc 1986; 32:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/25\">",
"      Sherman S, Ruffolo TA, Hawes RH, Lehman GA. Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology 1991; 101:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/26\">",
"      Kasmin FE, Cohen D, Batra S, et al. Needle-knife sphincterotomy in a tertiary referral center: efficacy and complications. Gastrointest Endosc 1996; 44:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/27\">",
"      Dowsett JF, Polydorou AA, Vaira D, et al. Needle knife papillotomy: how safe and how effective? Gut 1990; 31:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/28\">",
"      Manes G, Di Giorgio P, Repici A, et al. An analysis of the factors associated with the development of complications in patients undergoing precut sphincterotomy: a prospective, controlled, randomized, multicenter study. Am J Gastroenterol 2009; 104:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/29\">",
"      Kaffes AJ, Sriram PV, Rao GV, et al. Early institution of pre-cutting for difficult biliary cannulation: a prospective study comparing conventional vs. a modified technique. Gastrointest Endosc 2005; 62:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/30\">",
"      Vandervoort J, Carr-Locke DL. Needle-knife access papillotomy: an unfairly maligned technique? Endoscopy 1996; 28:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/31\">",
"      Harewood GC, Baron TH. An assessment of the learning curve for precut biliary sphincterotomy. Am J Gastroenterol 2002; 97:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/32\">",
"      Howell DA, Hanson BL, Ku PM, et al. Endoscopic therapy of type II sphincter of Oddi dysfunction (SOD) without manometry (abstract). Gastrointest Endosc 1998; 47:AB117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27157/abstract/33\">",
"      Mavrogiannis C, Liatsos C, Romanos A, et al. Needle-knife fistulotomy versus needle-knife precut papillotomy for the treatment of common bile duct stones. Gastrointest Endosc 1999; 50:334.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 642 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_33_27157=[""].join("\n");
var outline_f26_33_27157=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H83651580\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SPHINCTER OF ODDI DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COMPARISON OF TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83651580\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=related_link\">",
"      Clinical manifestations and diagnosis of sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=related_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/10/25767?source=related_link\">",
"      Precut (access) papillotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/5/7254?source=related_link\">",
"      Precut sphincterotomy: Another perspective on indications and techniques",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_33_27158="Intercostal nerve block";
var content_f26_33_27158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Intercostal nerve block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 690px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The rib is palpated in the mid-posterior axillary line and a needle inserted at the inferior border of the rib. If the needle comes in contact with bone, the needle is \"walked off\" the bone inferiorly. The needle is advanced 0.5 cm and local anesthetic injected (bupivacaine 0.25 to 0.5 percent, lidocaine 1 to 2 percent, ropivacaine 0.5 to 0.75 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_33_27158=[""].join("\n");
var outline_f26_33_27158=null;
var title_f26_33_27159="Auricular inflammation RPC";
var content_f26_33_27159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81482%7ERHEUM%2F82354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81482%7ERHEUM%2F82354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Auricular inflammation in relapsing polychondritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 228px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acute auricular inflammation in a patient with relapsing polychondritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jerome H Herman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cauliflower ear in relapsing polychondritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Auricular distortion in relapsing polychondritis induced by destructive changes in supporting structures of connective tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jerome H Herman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_33_27159=[""].join("\n");
var outline_f26_33_27159=null;
var title_f26_33_27160="Prescription drug abuse and addiction: Prevention, identification, and management";
var content_f26_33_27160=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prescription drug abuse and addiction: Prevention, identification, and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/33/27160/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27160/contributors\">",
"     Bonnie B Wilford, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27160/contributors\">",
"     Theodore V Parran, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27160/contributors\">",
"     Robert L DuPont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/33/27160/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27160/contributors\">",
"     Andrew J Saxon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/33/27160/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27160/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/33/27160/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 3, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H415115529\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prescription drug abuse involves the use of a medication, usually by self-administration, in a manner that deviates from medical, legal, and social standards [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/1\">",
"     1",
"    </a>",
"    ]. In addiction, the use becomes chronic and is accompanied by impaired control over drug use, compulsive use, continued use despite harm, or cravings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medications with potential for abuse and addiction are regulated, restricting whether and how they can be prescribed. In the US, these drugs are referred to as \"controlled substances\" and include opiates, stimulants, and anxiolytics.",
"   </p>",
"   <p>",
"    This topic addresses the prevention, identification, and management of prescription drug abuse and addiction. Clinical features, epidemiology, and contributing factors of prescription drug abuse and addiction are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36535?source=see_link\">",
"       \"Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"       \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"       \"Treatment of opioid abuse and dependence\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=see_link\">",
"       \"Cocaine abuse and dependence in adults\"",
"      </a>",
"      .)",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299073154\">",
"    <span class=\"h1\">",
"     ETHICAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ethical issues involved in decision-making regarding initiation or continuation of controlled drug prescribing can be complex [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. They include, but are not limited to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The nature of the clinician-patient relationship and the premise of trust",
"     </li>",
"     <li>",
"      Patient autonomy versus clinician beneficence",
"     </li>",
"     <li>",
"      Informed consent and the patient's right to know",
"     </li>",
"     <li>",
"      Obligations to relieve suffering where possible",
"     </li>",
"     <li>",
"      The principle of \"do no harm\" or non-malfeasance",
"     </li>",
"     <li>",
"      Patient abandonment and the obligation to treat.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Consideration of these issues serves as the basis of many of the clinical recommendations that follow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415115542\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventing the abuse and diversion of controlled medications requires that the physician understands the responsibilities that come with the authority to prescribe these drugs, and adopts sound clinical practices for prescribing them. &nbsp;",
"   </p>",
"   <p>",
"    Sound prescribing practice entails thorough patient assessment, careful drug selection, clear communication with appropriate individuals (eg, patient, family, other health professionals), minimizing the potential for prescription alteration, monitoring response to treatment, and maintaining clear and accurate records [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415115549\">",
"    <span class=\"h2\">",
"     Physicians&rsquo; responsibilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each time a physician writes a prescription, he or she assumes a variety of responsibilities by statute and custom. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A social responsibility to uphold the law and help protect society from drug abuse.",
"     </li>",
"     <li>",
"      A professional responsibility to prescribe controlled drugs appropriately, guarding against abuse while assuring that their patients have medication available when they need it.",
"     </li>",
"     <li>",
"      A personal responsibility to protect their practices from becoming easy targets for drug diversion, which could result in disciplinary action against the physician and possible loss of the license to practice medicine.",
"     </li>",
"     <li>",
"      A legal responsibility to learn the relevant requirements of state and Federal law as they govern the prescribing and use of controlled drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415115556\">",
"    <span class=\"h2\">",
"     Patient assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before prescribing a psychoactive drug, the clinician must weigh the benefits against the risks for the individual patient [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. &nbsp;The risk of prescription drug misuse and abuse varies from one individual to another. A thorough history should be taken of the patient&rsquo;s current and past substance misuse and abuse of alcohol, illicit drugs, and prescription medications. Consideration should be given to the patient's veracity and reliability in taking medications. Specific questions to be asked are described below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36535?source=see_link\">",
"     \"Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the past six months, have you taken any medications to help you calm down, keep from getting nervous or upset, raise your spirits, or make you feel better?",
"     </li>",
"     <li>",
"      Have you been taking any medication to help you sleep? Have you been using alcohol for this purpose?",
"     </li>",
"     <li>",
"      Have you ever taken a medication to help you with a drug or alcohol problem?",
"     </li>",
"     <li>",
"      Have you ever taken a medication for a nervous stomach?",
"     </li>",
"     <li>",
"      Have you taken a medication to give you more energy or to cut down on your appetite?",
"     </li>",
"     <li>",
"      Have you ever taken over-the-counter cold preparations other than when you have cold symptoms? Do you take over-the-counter diet pills?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Positive answers to any of these questions warrant further investigation. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H729039390\">",
"    <span class=\"h3\">",
"     New patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional precautions should be taken before prescribing a controlled drug to a new patient. Determine who has been providing medical care in the past, what drug(s) have been prescribed, and for what indications. The Prescription Monitoring Program (PMPs) has been adopted by 35 states in the US. &nbsp;That program can be used to identify other physicians who are prescribing for the patient, who should be consulted about the reason for prescribing, and the patient&rsquo;s response to treatment. After obtaining patient consent, medical records from past treatment episodes should be obtained and reviewed. &nbsp;If possible, this should take place before controlled medications are prescribed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281864217\">",
"    <span class=\"h2\">",
"     Determination of treatment goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relief of symptoms is a legitimate goal of medical practice, but patients differ in pain tolerance and the threshold with which they report symptoms. Patients should be helped to understand that restoration of function is the goal, rather than complete relief of symptoms. Communicating this is essential when treating chronic pain and other long-term medical problems. In this regard, it is helpful to develop a treatment plan that incorporates both pharmacologic and nonpharmacologic approaches (such as physical therapy).",
"   </p>",
"   <p>",
"    Once the optimum drug(s) has been selected, the dose, schedule and formulation should be determined. Aspects of drug formulation can reduce tampering and limit prescription drug abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some instances, the addition of secondary ingredients can deter abuse. For example, secondary ingredients may cause aversive side effects when taken in quantity (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      ) or when taken by a nonoral route (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Controlled-release delivery systems can slow the speed with which drugs enter the brain and thus decrease the potential for abuse. In one study, the immediate-release formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      was more reinforcing and thus had greater abuse potential than equivalent plasma levels of the extended-release formulation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/10\">",
"       10",
"      </a>",
"      ]. Drugs formulated as patches, such as certain opioids and ADHD medications, have lower abuse potential because the patch releases the drug gradually.",
"     </li>",
"     <li>",
"      Prodrugs are under development that require enzymatic metabolism to be converted to the active component [",
"      <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/11\">",
"       11",
"      </a>",
"      ]. Prodrugs could deter drug abuse through their slower onset of action, as well as their resistance to activation if taken by any route other than oral, for those prodrugs dependent on enzymatic activity in the gut.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415115577\">",
"    <span class=\"h2\">",
"     Communicating with the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should stress that any medication, no matter how helpful, is only part of an overall treatment plan. Plans to monitor for efficacy, safety, compliance, and development of tolerance must be clearly communicated to the patient.",
"   </p>",
"   <p>",
"    Patients should be informed at the time a controlled drug is prescribed that it is illegal to sell, give away, or otherwise share the medication with others, including family members. The patient's obligation extends to keeping all abusable medications in a locked cabinet or otherwise restricting access, and to safely disposing of any unused supply, as through drug &ldquo;take-back&rdquo; programs sponsored by many pharmacies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415115584\">",
"    <span class=\"h3\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process of educating patients on the risks and benefits of drug therapy includes addressing the risks of misuse and abuse. &nbsp;Issues that should be addressed include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The associated ethical and legal obligations for patient and clinician.",
"     </li>",
"     <li>",
"      The potential for physical injury and cognitive impairment.",
"     </li>",
"     <li>",
"      Possible adverse effects caused by interactions with other drugs, including alcohol, and the risk of accidental overdose.",
"     </li>",
"     <li>",
"      For women, the implications of becoming pregnant while taking opioids and the adverse effects associated with in utero exposure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link\">",
"       \"Overview of illicit drug use in pregnant women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=see_link\">",
"       \"Infants of mothers with substance abuse\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415115591\">",
"    <span class=\"h3\">",
"     Treatment agreements",
"    </span>",
"    &nbsp;&mdash;&nbsp;A growing number of clinicians use written treatment agreements to spell out the obligations of physician and patient when prescribing and using controlled drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topics related to use of controlled drugs that can be addressed through treatment agreements or informed consent include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Agreement to obtain prescriptions for a class of controlled medication from only one clinician and, preferably, from one designated pharmacy. Identifying the specified pharmacy in the document is helpful.",
"     </li>",
"     <li>",
"      Agreement to take the medication only as prescribed, with options provided that allow the patient to make some adjustments in response to changes in symptoms.",
"     </li>",
"     <li>",
"      Acknowledgment that patients are responsible for arranging refills during regular office hours. They must plan ahead, and not require medication refills during weekends or clinician vacation periods.",
"     </li>",
"     <li>",
"      Agreement that the patient will stop taking all other controlled medications of that type, unless explicitly told to continue them.",
"     </li>",
"     <li>",
"      Agreement that violation of the terms of the agreement may result in discontinuation of the controlled medication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Putting the agreement in writing can facilitate communication between the clinician and patient. Having the patient sign the agreement provides documentation of their discussion. The figure shows a patient form designed for long-term controlled-drug management (",
"    <a class=\"graphic graphic_form graphicRef61018 graphicRef72823 graphicRef51850 \" href=\"UTD.htm?18/33/18970\">",
"     form 1A-C",
"    </a>",
"    ). It is helpful to give the patient a copy of the agreement to carry with him or her, to document the source and reason for any controlled drugs in his or her possession. Some physicians provide a laminated card that identifies the individual as a patient of their practice.",
"   </p>",
"   <p>",
"    A sample patient form addressing management of controlled medications is provided in the figures (",
"    <a class=\"graphic graphic_form graphicRef61018 graphicRef72823 graphicRef51850 \" href=\"UTD.htm?18/33/18970\">",
"     form 1A-C",
"    </a>",
"    ). The influence of treatment agreements on patient behavior and outcomes has not been clearly established [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/13\">",
"     13",
"    </a>",
"    ]. No randomized trials have been conducted, and data from small, retrospective studies have been mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, such forms can help clinicians set and communicate boundaries around long-term prescribing of controlled drugs and enhance their comfort when prescribing within those boundaries [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415115598\">",
"    <span class=\"h2\">",
"     Prescriptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper execution of the prescription order form can prevent manipulation by the patient or others intent on obtaining drugs for nonmedical purposes.",
"   </p>",
"   <p>",
"    Every prescription order for controlled substances in the US must include the following information. Many states have additional requirements.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Date",
"     </li>",
"     <li>",
"      Name and address of the patient",
"     </li>",
"     <li>",
"      Name and address of the prescribing clinician",
"     </li>",
"     <li>",
"      Drug Enforcement Administration (DEA) number of the prescribing clinician (in the United States )",
"     </li>",
"     <li>",
"      Signature of the prescribing clinician",
"     </li>",
"     <li>",
"      Name and quantity of the drug prescribed",
"     </li>",
"     <li>",
"      Directions for use",
"     </li>",
"     <li>",
"      Refill information",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians should not preprint DEA numbers on forms (",
"    <a class=\"graphic graphic_form graphicRef61018 graphicRef72823 graphicRef51850 \" href=\"UTD.htm?18/33/18970\">",
"     form 1A-C",
"    </a>",
"    ), so as to make it more difficult for stolen forms to be used. Prescription forms should be made tamper-resistant; some are printed on paper that shows any erasures or ink removers. As with all prescriptions, clear writing is essential. Spelling out the quantity to be dispensed (in addition to the numeric figure) may limit tampering. The prescription order should specify both the milligram dose along with the volume of solution to be taken at any given time for oral liquids, and specify the concentration to be used. Optimally, electronic prescribing with direct transmission to the pharmacy can prevent transcription errors and tampering.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415115605\">",
"    <span class=\"h3\">",
"     Forged prescriptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A forger often begins with a legitimate prescription order, which is then photocopied. Many drug-seekers are constantly on the lookout for blank forms, which should be stored in a safe place and not left in exam rooms. Clinicians should immediately report the theft or loss of blank prescription forms (in the US, to the nearest DEA field office and to the state board of medicine or pharmacy). Forgers sometimes create their own prescription forms, using the names of physicians who recently retired, left the state, or died.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415115612\">",
"    <span class=\"h3\">",
"     Altered prescriptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A figure",
"    <strong>",
"    </strong>",
"    shows three prescriptions, before and after they were altered (",
"    <a class=\"graphic graphic_figure graphicRef73560 \" href=\"UTD.htm?34/31/35322\">",
"     figure 1",
"    </a>",
"    ). In each case, the drug-seeker used a pen with the same color ink. In the first example, the dispensing number, written only in arabic numerals, was easily altered by the forger. The second and third examples show that dispensing numbers written out in Roman numerals or words also can be changed. Some drug-seekers alter the number of refills on the prescription as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26688275\">",
"    <span class=\"h3\">",
"     Refill requests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limiting the number of refills allows the clinician to monitor the patient's response periodically, which is particularly important during long-term therapy. After individual responses and appropriate dose have been determined through monitoring, refill policy may be eased for the patient's convenience (except for Schedule II drugs, where refills are not allowed).",
"   </p>",
"   <p>",
"    Requests for early refills are a warning sign of drug misuse or abuse. &nbsp;Drugs sometimes are legitimately lost or accidentally destroyed, but multiple requests for early refills should be treated as evidence of aberrant medication use and handled accordingly.",
"   </p>",
"   <p>",
"    In a non-emergency situation, the patient should be seen in the office as soon as possible, and an amount of medications prescribed only sufficient only to last until the date of the appointment. In an emergency situation, the clinician should prescribe no more than one day's supply of a drug. The patient should be seen in the office immediately or directed to a hospital emergency department. At a minimum, the patient's identity should be verified by proper photo identification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415115619\">",
"    <span class=\"h2\">",
"     Treatment with controlled medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basic principles for clinical management when prescribing controlled medications, particularly on a long-term basis, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Do not agree to prescribe controlled drugs on a chronic basis in the face of diagnostic uncertainty. As an example, if the source of chronic pain is unclear, a trial of nonpharmacologic therapy may be indicated before prescribing an opioid analgesic.",
"     </li>",
"     <li>",
"      Do not prescribe controlled drugs to self, family or close friends or colleagues. Sufficient therapeutic distance is necessary to effectively monitor a patient. In addition, these practices violate the policies of many state medical boards in the US.",
"     </li>",
"     <li>",
"      Never prescribe a controlled drug unless there is a medical record to document the presence of a physician-patient relationship and a legitimate medical purpose for the prescription. (See",
"      <a class=\"local\" href=\"#H415115640\">",
"       'Documentation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Discontinue controlled drug prescribing or substantially revise the therapeutic regimen if the patient demonstrates out-of-control behavior. (See",
"      <a class=\"local\" href=\"#H299074342\">",
"       'Distinguishing medical use from abuse'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      No treatment program should be left open-ended. Where feasible, planned termination of medication therapy is a reasonable goal because it can limit drug exposure.",
"     </li>",
"     <li>",
"      Become familiar with opioid, benzodiazepine, and stimulant pharmacology and withdrawal management. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=see_link\">",
"       \"Benzodiazepine poisoning and withdrawal\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=see_link\">",
"       \"Opioid withdrawal in the emergency setting\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20103?source=see_link\">",
"       \"Opioid withdrawal in adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1191?source=see_link\">",
"       \"Opioid detoxification during treatment for addiction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beware the \"heart-sink\" patient (the one whose name on the schedule makes your heart sink). If this sensation is associated with prescribing controlled drugs, re-assess the patient for addiction and, if indicated, refer the patient for specialized assessment and treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415115626\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine medication monitoring visits should be conducted when prescribing a controlled drug. Such visits should be conducted weekly at the beginning of therapy for patients you are concerned about, then monthly or bimonthly as the patient&rsquo;s response stabilizes. Monitoring should include both subjective and objective data: the patient's report of symptom response and side effects, clinician assessment of signs of intoxication or abuse, and body weight, pulse rate, temperature, blood pressure, and urine or serum drug levels. Use of a structured flow chart is encouraged to avoid skipping steps and to document results systematically (",
"    <a class=\"graphic graphic_form graphicRef73967 \" href=\"UTD.htm?42/0/43023\">",
"     form 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Drug testing is the single most useful laboratory test to monitor patients receiving long-term controlled drug prescriptions. Toxicology testing is useful in establishing compliance and in detecting the use of other, non-prescribed controlled substances. A high percentage of patients who abuse prescribed controlled substances also abuse other drugs that are readily identified through routine urine drug screens. In addition, the presence of unusually low serum drug levels indicates noncompliance and raises the possibility that a patient is diverting his or her prescription to others for sale.",
"   </p>",
"   <p>",
"    Asking the patient to keep a log of signs and symptoms can engender a sense of participation in the treatment program and improve clinician review of therapeutic progress and adverse events. Signs of therapeutic failure or unacceptable adverse drug reactions require alteration of therapy.",
"   </p>",
"   <p>",
"    Whenever the best clinical course is not clear or the patient&rsquo;s response is not as expected, consultation with another physician should be obtained. One option is an addiction specialist. &nbsp;Generally, the results of the consultation should be discussed with the consulting physician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415115640\">",
"    <span class=\"h3\">",
"     Documentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of accurate and up to date documentation cannot be over-emphasized. Having a complete medical record protects both the clinician and patient. Clinicians need to know and understand laws and regulatory requirements. In the US, the Board of Medical Licensure or the Board of Pharmacy (or their equivalent) in each state can provide information about the relevant requirements.",
"   </p>",
"   <p>",
"    At a minimum, patient records should contain the following information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient history and physical examination &mdash; Include a history of all controlled drugs used to treat the patient in the past, any nonmedical drug use, patient allergies, personal and family history of alcoholism or other addiction, major depression or other psychiatric disorder. It is wise to obtain the patient's records directly from physicians who have treated him or her in the past. Caution should be exercised in accepting records supplied by patients, as these occasionally are fraudulent.",
"     </li>",
"     <li>",
"      Documentation of the treatment plan &mdash; Provide the results of diagnostic investigations (including laboratory tests), as well as evidence of clear-cut, individualized treatment objectives and the clinical decision making leading to the choice of therapy. Treatment agreements between clinician and patient should also be included in the medical record.",
"     </li>",
"     <li>",
"      Use of consultants &mdash; A written consultation report added to the patient's medical record.",
"     </li>",
"     <li>",
"      Prescription orders &mdash; The patient record must include all prescription orders, whether written or telephoned. Written instructions for the use of all medications should be given to the patient and documented in the record. (See",
"      <a class=\"local\" href=\"#H415115598\">",
"       'Prescriptions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence of monitoring visits &mdash; Medication monitoring visits should be carefully documented in the medical record. In the office of a primary care physician these visits may be conducted by a nurse or other member of the physician&rsquo;s staff; they should be documented in the same manner as a visit with the physician. (See",
"      <a class=\"local\" href=\"#H415115626\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Report of outcomes",
"      <strong>",
"      </strong>",
"      &mdash; Treatment response should be well documented, including regimens tried and failed. Even if the outcome is less than optimal, thorough records protect both the physician's and the patient's interests.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26688282\">",
"    <span class=\"h1\">",
"     IDENTIFYING MISUSE, ABUSE AND ADDICTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299074342\">",
"    <span class=\"h2\">",
"     Distinguishing medical use from abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;In monitoring patients' response to treatment, it is important for the physicians to clearly distinguish between appropriate medical use of controlled substances and misuse and abuse. Signs of typical medical and nonmedical use of controlled substances include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36535?source=see_link\">",
"     \"Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical use typically is oral; nonmedical use often involves routes of administration other than oral.",
"     </li>",
"     <li>",
"      Medical use is at routine doses; non-medical use often involves escalating and excessive doses that may be taken in binges. &nbsp;",
"     </li>",
"     <li>",
"      Medical use does not usually occur concurrently with use of other mind-altering substances; non-medical use frequently involves co-administration with other drugs (eg, alcohol, marijuana, or other illicit substances)",
"     </li>",
"     <li>",
"      Medical users do not expect or wish to experience altered perception as a result of their drug use; nonmedical use occurs with the patient expectation of \"getting high\" or other altered consciousness.",
"     </li>",
"     <li>",
"      Medical use most often occurs in private and in the course of a routine daily pattern; nonmedical use may occur erratically, in the company of others, and outside the home.",
"     </li>",
"     <li>",
"      Patients who develop addiction pathology related to a prescribed drug often report that the medicine is ineffective and therefore engage in dose escalation and early requests for refills. [",
"      <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These distinctions need to be explained to patients for whom controlled substances are prescribed, so that patients who use these substances medically can be reassured and those who do not use them appropriately can recognize the pathological nature of their drug-using behavior. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299074294\">",
"    <span class=\"h2\">",
"     Characteristic behaviors",
"    </span>",
"    &nbsp;&mdash;&nbsp;When diagnosing a patient with prescription drug abuse or addiction, the clinician should take note of behaviors characteristic of these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/18\">",
"     18",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Requests for early refills. Examples include the patient who makes an urgent, unscheduled visit late in the day with reasons for running out of medication early, such as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      &ldquo;I took too many&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Lost the prescription&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Washed it with the laundry&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Spilled it in the toilet&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;It was stolen.&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;The dog ate it&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;The pharmacist shorted the count&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multisourcing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Visiting multiple physicians",
"     </li>",
"     <li>",
"      Recruiting surrogates to obtain the medication",
"     </li>",
"     <li>",
"      Purchasing drugs from illicit drug dealers or over the Internet &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intoxicated behaviors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Slurred or disinhibited calls to the office",
"     </li>",
"     <li>",
"      Presenting to pharmacies under the influence",
"     </li>",
"     <li>",
"      Emergency department visits for repeated falls, other traumatic injuries, accidental overdose &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pressuring behaviors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Begging or pleading",
"     </li>",
"     <li>",
"      Excessive compliments",
"     </li>",
"     <li>",
"      Breaching boundaries",
"     </li>",
"     <li>",
"      Threats of harm to self or others",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the cause of a patient&rsquo;s aberrant behaviors is not clear, the patient should be referred to a health professional with more experience in the assessment and treatment of concurrent substance use disorders. Consultation or joint management with an addiction medicine or addiction psychiatry specialist can be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415115661\">",
"    <span class=\"h2\">",
"     Pseudoaddiction",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Pseudoaddiction\" describes a situation in which a patient&rsquo;s legitimate chronic pain condition is undertreated with pain medication, leading the patient to act in a way that resembles addictive behavior. Pseudoaddiction should be part of the differential diagnosis of prescription drug abuse and addiction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. The situation arises when a clinician is reluctant to provide enough of a controlled drug to provide adequate symptom relief for a patient who requires long-term treatment. This leads to a patient who is either chronically undertreated or intermittently put into withdrawal due to unclear dosing instructions (eg, &ldquo;q4h prn&rdquo; and #90",
"    <span class=\"nowrap\">",
"     tablets/month).",
"    </span>",
"    The patient responds with a series of \"conditioned behaviors\" focused on acquisition of the controlled drug that can appear to indicate aberrant addictive type behaviors. However, in pseudoaddiction, the behaviors disappear when an adequate amount of the drug is obtained and does not reappear. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415115668\">",
"    <span class=\"h1\">",
"     ADDRESSING MISUSE, ABUSE AND ADDICTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of a patient who is misusing or abusing a prescribed controlled drug presents a major therapeutic opportunity. Patients misusing these medications should be educated about their appropriate use and risks of misuse. Education includes clear instructions about how to take medicine and clear expectations that medications will be used only for the condition for which it was prescribed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who fail to change behavior after such education are moving into the area of medication abuse. When abuse is detected, it is important for the clinician to maintain a professional demeanor and convey direct empathic concern in a nonjudgmental fashion. &nbsp;Advice should relate to the patient&rsquo;s primary complaint, such as &ldquo;I know you have been suffering with your back pain and I want to help you, but I am concerned that your use of pain medications has become a problem&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/5\">",
"     5",
"    </a>",
"    ]. Specific steps may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Modifying the patient&rsquo;s treatment plan, in consultation with the patient and the patient's family, to incorporate therapies for the patient&rsquo;s pain or other disorder that minimize the potential for drug misuse and abuse. &nbsp;This may involve escalating the use of nonpharmacologic therapies or switching to medications with low or no abuse potential.",
"     </li>",
"     <li>",
"      Referral to an addiction specialist for assessment and, if indicated, placement in a specialized inpatient or outpatient addiction treatment program. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1191?source=see_link\">",
"       \"Opioid detoxification during treatment for addiction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"       \"Treatment of opioid abuse and dependence\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Encouraging the patient to participate in a 12-step mutual support program such as Alcoholics Anonymous or Narcotics Anonymous.",
"     </li>",
"     <li>",
"      Treatment of any previously undiagnosed medical or psychiatric problems.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Certain situations may warrant immediate cessation of a controlled medication. These generally occur when out-of-control behaviors indicate that continued prescribing is unsafe or causing harm to the patient (eg, accidental or intentional overdose altering prescriptions, threatening office staff and selling or buying medications from others). When such events arise, it is important take several actions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cease prescribing, explaining to the patient that continued prescribing is unsafe and therefore medically inappropriate.",
"     </li>",
"     <li>",
"      Demonstrate a positive regard for the person but show no tolerance for the behaviors related to drug misuse or abuse. Use non-judgmental and patient-centered terminology. The goal is to deescalate conflict in the clinician-patient encounter, without relenting and prescribing when good medical judgment dictates otherwise [",
"      <a class=\"abstract\" href=\"UTD.htm?26/33/27160/abstract/10,22-24\">",
"       10,22-24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Educate the patient about signs and symptoms of spontaneous opioid or benzodiazepine withdrawal (",
"      <a class=\"graphic graphic_table graphicRef81045 \" href=\"UTD.htm?21/47/22267\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Urge the patient to accept a referral for medically supervised withdrawal and substance abuse treatment. If the patient has received previous substance abuse treatment, he or she should be strongly urged to re-engage with that program. &nbsp;",
"     </li>",
"     <li>",
"      In many cases, the clinician can continue to treat the patient without continuing to prescribe controlled drugs. Drug-seeking patients often have real medical problems that deserve the same quality medical care offered to any patient",
"     </li>",
"     <li>",
"      If discontinuing treatment, the physician should be sure to follow the rules for terminating treatment established by the appropriate regulating authority (eg, the state medical board in the US).",
"     </li>",
"     <li>",
"      The patient should not be provided a supply of the controlled drug for use until further treatment can be obtained, even if the patient agrees to pursue substance abuse treatment. Prescribing the drug in these situations may be illegal if interpreted as continued prescribing in the face of knowingly doing harm to a patient. It is medically inadvisable, as it may defer the patient's acceptance of his or her need for treatment.",
"     </li>",
"     <li>",
"      The role of the physician in reporting a patient&rsquo;s prescription drug abuse to other health care providers, pharmacies, or the criminal justice system is subject to laws and regulations and is controversial. Some general principles in the US are described below, but rules may vary by state or country and should be verified locally.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Reporting to other physicians may be subject to patient confidentially regulations.",
"     </li>",
"     <li>",
"      Communication among physicians within a health care system or organization may be more permissible than communication between health care organizations.",
"     </li>",
"     <li>",
"      Reporting pharmacy-related information (eg, use of an altered prescription), as opposed to clinical information, to pharmacies or to law enforcement is typically permissible in the US.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the clinician fails to respond firmly to out-of-control behaviors, the patient's abuse or addiction is likely to progress, with increasingly dangerous behaviors and adverse consequences. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36535?source=see_link&amp;anchor=H268753674#H268753674\">",
"     \"Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors\", section on 'Impact of the problem'",
"    </a>",
"    .) In addition, medical practices that prescribe in the face of abuse or addiction can begin to attract more patients with abuse problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/21/7506?source=see_link\">",
"       \"Patient information: Prescription drug abuse (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415115675\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preventing abuse and dependence of controlled medication requires the physician to understand the clinical, regulatory, and legal responsibilities that come with the authority to prescribe these drugs. (See",
"      <a class=\"local\" href=\"#H415115542\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thorough patient assessment, careful drug selection, clear communication with the patient, family, and other health professionals, minimizing the potential for prescription alteration, monitoring response to treatment, and maintaining accurate and clear records can all contribute to preventing prescription drug abuse and dependence. (See",
"      <a class=\"local\" href=\"#H415115542\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest use of written informed consent and treatment agreement documents when initiating longitudinal prescribing of a controlled medication (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). &nbsp;Such an agreement, spells out risks, benefits, rights and responsibilities of the patient and doctor. (See",
"      <a class=\"local\" href=\"#H415115591\">",
"       'Treatment agreements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Only prescribe a controlled drug when there is a legitimate medical purpose and a medical record that documents the presence of a physician-patient relationship. (See",
"      <a class=\"local\" href=\"#H415115619\">",
"       'Treatment with controlled medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Warning signs of abuse of or addiction to the drug include early requests for refills, obtaining the medication from multiple doctors or pharmacies, and exhibiting intoxicated behaviors or pressuring behaviors. (See",
"      <a class=\"local\" href=\"#H299074342\">",
"       'Distinguishing medical use from abuse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Detecting that a patient is abusing a prescribed controlled medication presents a therapeutic opportunity. The clinician should meet with the patient and family, develop a treatment plan for the abuse or addiction, and treat any co-existing medical conditions. (See",
"      <a class=\"local\" href=\"#H415115668\">",
"       'Addressing misuse, abuse and addiction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Medical Association, Council on Scientific Affairs, Drug Abuse Related to Prescribing Practices, Report to the House of Delegates, The Association, Chicago, IL 1981 (reaffirmed 1991, 2001).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/2\">",
"      Schuster CR. History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs. Drug Alcohol Depend 2006; 83 Suppl 1:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/3\">",
"      Parran T Jr. Prescription drug abuse. A question of balance. Med Clin North Am 1997; 81:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/4\">",
"      Longo LP, Parran T Jr, Johnson B, Kinsey W. Addiction: part II. Identification and management of the drug-seeking patient. Am Fam Physician 2000; 61:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/5\">",
"      Isaacson JH, Hopper JA, Alford DP, Parran T. Prescription drug use and abuse. Risk factors, red flags, and prevention strategies. Postgrad Med 2005; 118:19.",
"     </a>",
"    </li>",
"    <li>",
"     Database of State Statutes, Regulations, and Other Official Government Policies file://www.painpolicy.wisc.edu/matrix.htm (Accessed on July 09, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/7\">",
"      Liebschutz JM, Saitz R, Weiss RD, et al. Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain. J Pain 2010; 11:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/8\">",
"      McCabe SE, Boyd CJ, Cranford JA, Teter CJ. Motives for nonmedical use of prescription opioids among high school seniors in the United States: self-treatment and beyond. Arch Pediatr Adolesc Med 2009; 163:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/9\">",
"      Turk DC, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. Clin J Pain 2008; 24:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/10\">",
"      Clark WD. The medical interview: focus on alcohol problems. Hosp Pract (Off Ed) 1985; 20:59, 62, 65 passim.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/11\">",
"      Coleman JJ, Bensinger PB, Gold MS, et al. Can drug design inhibit abuse? J Psychoactive Drugs 2005; 37:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/12\">",
"      Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008; 9:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/13\">",
"      Arnold RM, Han PK, Seltzer D. Opioid contracts in chronic nonmalignant pain management: objectives and uncertainties. Am J Med 2006; 119:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/14\">",
"      Dunbar SA, Katz NP. Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: report of 20 cases. J Pain Symptom Manage 1996; 11:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/15\">",
"      Burchman SL, Pagel PS. Implementation of a formal treatment agreement for outpatient management of chronic nonmalignant pain with opioid analgesics. J Pain Symptom Manage 1995; 10:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/16\">",
"      Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005; 6:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/17\">",
"      Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006; 83 Suppl 1:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/18\">",
"      Chou R, Fanciullo GJ, Fine PG, et al. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009; 10:131.",
"     </a>",
"    </li>",
"    <li>",
"     College of Physicians and Surgeons of Ontario (CPSO). Methadone for pain guidelines, The College (Ed), Ontario, Canada 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/20\">",
"      Weissman DE, Haddox JD. Opioid pseudoaddiction--an iatrogenic syndrome. Pain 1989; 36:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/21\">",
"      Weissman DE. Understanding pseudoaddiction. J Pain Symptom Manage 1994; 9:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/22\">",
"      Heit HA. The truth about pain management: the difference between a pain patient and an addicted patient. Eur J Pain 2001; 5 Suppl A:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27160/abstract/23\">",
"      Clark WD. Alcoholism: blocks to diagnosis and treatment. Am J Med 1981; 71:275.",
"     </a>",
"    </li>",
"    <li>",
"     Drug Abuse Web Module. Available through Doc.Com file://webcampus.drexelmed.edu/doccom (Accessed on August 12, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15236 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_33_27160=[""].join("\n");
var outline_f26_33_27160=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H415115675\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H415115529\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H299073154\">",
"      ETHICAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H415115542\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H415115549\">",
"      Physicians&rsquo; responsibilities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H415115556\">",
"      Patient assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H729039390\">",
"      - New patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H281864217\">",
"      Determination of treatment goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H415115577\">",
"      Communicating with the patient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H415115584\">",
"      - Informed consent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H415115591\">",
"      - Treatment agreements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H415115598\">",
"      Prescriptions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H415115605\">",
"      - Forged prescriptions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H415115612\">",
"      - Altered prescriptions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26688275\">",
"      - Refill requests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H415115619\">",
"      Treatment with controlled medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H415115626\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H415115640\">",
"      - Documentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26688282\">",
"      IDENTIFYING MISUSE, ABUSE AND ADDICTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H299074342\">",
"      Distinguishing medical use from abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H299074294\">",
"      Characteristic behaviors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H415115661\">",
"      Pseudoaddiction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H415115668\">",
"      ADDRESSING MISUSE, ABUSE AND ADDICTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H415115675\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/15236\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/15236|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/31/35322\" title=\"figure 1\">",
"      Altered prescriptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/15236|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?42/5/43091\" title=\"form 1A\">",
"      Patient consent form - page 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?8/21/8534\" title=\"form 1B\">",
"      Patient consent form - page 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?11/14/11488\" title=\"form 1C\">",
"      Patient consent form - page 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?42/0/43023\" title=\"form 2\">",
"      Pain flow chart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/15236|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/47/22267\" title=\"table 1\">",
"      Clinical features of opioid withdrawal",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=related_link\">",
"      Cocaine abuse and dependence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=related_link\">",
"      Infants of mothers with substance abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1191?source=related_link\">",
"      Opioid detoxification during treatment for addiction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20103?source=related_link\">",
"      Opioid withdrawal in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=related_link\">",
"      Opioid withdrawal in the emergency setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=related_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/21/7506?source=related_link\">",
"      Patient information: Prescription drug abuse (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36535?source=related_link\">",
"      Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_33_27161="Mild cognitive impairment: Epidemiology, pathology, and clinical assessment";
var content_f26_33_27161=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mild cognitive impairment: Epidemiology, pathology, and clinical assessment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/33/27161/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27161/contributors\">",
"     Eric M McDade, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27161/contributors\">",
"     Ronald C Petersen, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/33/27161/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27161/contributors\">",
"     Steven T DeKosky, MD, FAAN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/33/27161/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27161/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/33/27161/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25688360\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild cognitive impairment (MCI) is an intermediate state between normal cognition and dementia. While specific changes in cognition are frequently observed in normal aging, there is increasing evidence that some forms of cognitive impairment are recognizable as an early manifestation of dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/1\">",
"     1",
"    </a>",
"    ]. As the following topic review will highlight, MCI is a heterogeneous state and there remains controversy over aspects of the construct. However, the utility of this paradigm centers around the recognition that dementia is not a dichotomous state; thus refining our understanding of the layers of transition will improve the understanding of cognitive decline and ultimately benefit patients.",
"   </p>",
"   <p>",
"    This topic will review the definition of MCI and related terms, as well as the epidemiology, pathology, and clinical assessment of MCI. The prognosis and treatment of MCI and topics related to dementia, including diagnosis, treatment, risk factors, and prevention of dementia, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26138?source=see_link\">",
"     \"Mild cognitive impairment: Prognosis and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=see_link\">",
"     \"Treatment of dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=see_link\">",
"     \"Risk factors for dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41369?source=see_link\">",
"     \"Prevention of dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Alzheimer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild cognitive impairment (MCI) refers to cognitive impairment that does not meet the criteria for dementia. Several criteria for, and subtypes of, MCI have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These criteria and subtypes differ somewhat, although there is considerable overlap. In general, these criteria include a measurable deficit in cognition in at least one domain, in the absence of dementia or impairment in activities of daily living.",
"   </p>",
"   <p>",
"    As originally constructed, the concept of MCI emphasized memory impairment and its status as a precursor state for Alzheimer disease (AD). Subsequently, it was recognized that MCI can be heterogeneous in terms of clinical presentation, etiology, prognosis, and prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/3-5\">",
"     3-5",
"    </a>",
"    ], and the construct was expanded to broaden the scope of MCI to other cognitive domains, thereby extending the early detection of other dementias in their prodromal stages [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Although these criteria were developed as a concept relating early changes in specific cognitive domains to those areas most commonly affected in the disorders (eg, memory problems and AD), pathological and long-term clinical follow-up data to support this paradigm are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These criteria are imprecise. Considerable judgment is required in making the distinction between impairments that are normal for the elderly population and, on the other extreme, that do not represent dementia. What constitutes impairment in daily living is different for each individual. Such distinctions draw upon clinical expertise and do not rely on psychometric testing alone. These appraisals can differ between assessors and this may account for some of the conflicting results in studies of this disorder. Some clinicians and investigators have challenged specific aspects of the criteria including the requirements for subjective cognitive complaints and intact activities of daily living [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Amnestic MCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amnestic MCI is often thought of as a precursor to AD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/13\">",
"     13",
"    </a>",
"    ]. Amnestic MCI is the most common subtype with a ratio of 2:1 compared to nonamnestic MCI, although relative prevalence of MCI subtypes has varied among studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term MCI, without qualification, was traditionally and is still often used to refer to the amnestic type; however, using MCI without qualification is somewhat ambiguous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Single domain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amnestic MCI (aMCI) refers to those individuals with significantly impaired memory who do not meet criteria for dementia. The criteria originally outlined for MCI are understood to identify specifically this type [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Memory complaint, preferably corroborated by an informant",
"     </li>",
"     <li>",
"      Objective memory impairment (for age and education)",
"     </li>",
"     <li>",
"      Preserved general cognitive function",
"     </li>",
"     <li>",
"      Intact activities of daily living",
"     </li>",
"     <li>",
"      Not demented",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Memory impairments that qualify for MCI are generally represented by defects that are 1.5 standard deviations (SD) or more below age-corrected norms. While this seems straightforward, different tests of memory likely have different sensitivity and specificity, and norms are not available for all populations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Multiple domains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many individuals with aMCI complain only of memory loss; however, they may have additional subtle impairments in other cognitive domains that are revealed with careful neuropsychological testing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/7,16-18\">",
"     7,16-18",
"    </a>",
"    ]. Such persons may also manifest subtle problems with activities of daily living, but do not meet criteria for a formal diagnosis of dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/5\">",
"     5",
"    </a>",
"    ]. The multiple domains are, by definition, only slightly impaired (ie, less than 0.5 to 1 SD below age and education-matched normal subjects).",
"   </p>",
"   <p>",
"    These individuals often progress to meet criteria for AD or vascular dementia; in a minority of cases, the cognitive profile may simply reflect normal aging [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/5\">",
"     5",
"    </a>",
"    ]. The prognostic utility of the multiple domain form of aMCI remains unclear, as some studies have identified this as the highest risk category for conversion to dementia while others have exposed instability with some individuals returning to baseline level of function over time [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/7,19,20\">",
"     7,19,20",
"    </a>",
"    ]. Some of this variability may derive from different sources of subjects, for example, specialty clinics versus population cohorts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Non-amnestic MCI",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Single domain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of single domain non-amnestic MCI (naMCI) is similar to amnestic MCI, except that this form of MCI is characterized by a relatively isolated impairment in a single non-memory domain, such as executive functioning, language, or visual spatial skills [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/5\">",
"     5",
"    </a>",
"    ]. Depending upon the domain, individuals with this subtype of MCI may progress to other syndromes, such as frontotemporal dementia (FTD), primary progressive aphasia, dementia with Lewy bodies, progressive supranuclear palsy, or corticobasal degeneration. Individuals within this group appear to be at less of a risk of conversion to dementia, although supporting evidence is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/9,21\">",
"     9,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In certain disorders such as behavioral variant FTD, cognitive complaints are often preceded by significant alterations in behavior and comportment. Thus some have proposed the concept of mild behavioral impairment as a similar paradigm to recognize an additional group with increased risk of dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Multiple domains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who meet these criteria are affected in multiple domains with a relative sparing of memory problems. The substrate of multi-domain naMCI is felt to be that of degenerative disorders associated with tau, TAR DNA binding protein (TDP-43), and alpha-synuclein such as FTD and DLB [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Related terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many loosely related terms that have been used to describe constructs that are similar to or perhaps even the same as MCI, eg, incipient dementia, isolated memory impairment, dementia prodrome, minimal AD, predementia AD, prodromal AD, and early AD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/1,2,5,6,25,26\">",
"     1,2,5,6,25,26",
"    </a>",
"    ]. Most of these definitions do not overlap fully with the definition of MCI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concept of MCI perhaps reflects most closely the idea of \"cognitive impairment, no dementia\" (CIND) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/28\">",
"     28",
"    </a>",
"    ]. However, in contrast to the definition for the amnestic form of MCI, CIND relies less heavily on the presence of prominent memory deficits and includes in its definition the presence of a functional disability. It is a more inclusive definition than MCI, as is reflected by its higher prevalence. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Epidemiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    \"Age-associated memory impairment\" and \"age-associated cognitive decline\" (AACD) are also widely used and fairly well-known terms. However, these terms differ from MCI in that they were originally devised to define normal age associated memory and cognitive changes in older adults as referenced to young normal adult individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/1,29,30\">",
"     1,29,30",
"    </a>",
"    ]. AACD was developed as a way of better defining the cognitive changes in elderly patients compared to age-adjusted norms. AACD has more recently been recognized as identifying a state of impairment similar to MCI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/31\">",
"     31",
"    </a>",
"    ]. In MCI, memory impairments are referenced to age-adjusted norms.",
"   </p>",
"   <p>",
"    Studies of \"preclinical AD\" should be distinguished from studies of MCI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/32\">",
"     32",
"    </a>",
"    ]. In MCI studies, patients meet cognitive criteria for diagnosis, and are then followed prospectively to assess for conversion to AD. In contrast, \"preclinical AD\" studies usually examine information retrospectively, following the diagnosis of AD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings from epidemiological studies vary significantly, partially due to the differing diagnostic criteria, measuring instruments, definitions, and use of population verses clinic-based samples.",
"   </p>",
"   <p>",
"    Although the published prevalence rates vary from as low as 2 to 4 percent to greater than 20 percent, a number of prospective population based studies estimate the prevalence among older adults (&gt;70 years) to be between 14 and 18 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/1,4,10,14,33-36\">",
"     1,4,10,14,33-36",
"    </a>",
"    ]. Studies using different measures, such as \"age-associated cognitive decline,\" \"cognitive impairment, no dementia,\" and \"minimal dementia,\" estimate prevalences of 16 to 22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/2,10,28,37-39\">",
"     2,10,28,37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimates of incidence rates for MCI vary as well; a variety of population-based cohort studies have reported incidence rates in their elderly populations (&gt;65 to 75 years) of between 14 to 77 per 1000 patient years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/40-44\">",
"     40-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gender, race, increased age, and lower education are inconsistently associated with MCI in various studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/4,10,37,39,45-48\">",
"     4,10,37,39,45-48",
"    </a>",
"    ]. In a community-based study of adults ages 70 to 89 years, MCI was more common in men (OR = 1.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/39\">",
"     39",
"    </a>",
"    ]. Elevated blood pressure and diabetes (even in the absence of symptomatic cerebrovascular disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/34,45-52\">",
"     34,45-52",
"    </a>",
"    ] and apolipoprotein E epsilon 4 genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/53-55\">",
"     53-55",
"    </a>",
"    ] have also been associated with the risk of MCI, particularly amnestic MCI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathological studies suggest that MCI represents an early clinical expression of age-related neurodegenerative disease. Several autopsy studies have found that individuals with MCI, as a group, have Alzheimer disease (AD) pathology that is intermediate in severity between normal controls and persons with more advanced AD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/14,56-62\">",
"     14,56-62",
"    </a>",
"    ]. Some, but not all studies, find that pathologies consistent with other dementing processes (eg, Lewy body disease and cerebrovascular disease) are also over-represented in the MCI population compared with normal controls, although AD pathology usually predominates [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/13,56,63-65\">",
"     13,56,63-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of cholinergic markers in patients with MCI and early to late stages of AD are helping to elucidate the pathogenesis of AD and have challenged the hypothesis that cholinergic dysfunction is responsible for early cognitive dysfunction in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cognitive complaints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MCI, particularly the amnestic subtype, complain primarily of impaired memory. Subjective memory complaints have been demonstrated to predict cognitive decline [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. It is important to note, however, that difficulties with certain aspects of memory, such as recalling names, are frequently reported by normal elderly patients. Subjective reports of memory complaints can often reflect mode or affective state as well [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/66,69\">",
"     66,69",
"    </a>",
"    ]. Some have pointed out that subjective cognitive complaints may be an insensitive clinical criterion as well as a nonspecific one; some individuals who meet neuropsychological test criteria for MCI deny having significant memory problems [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the impaired awareness of deficits commonly present in patients with AD, patients with MCI are often particularly troubled by their symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/68,70,71\">",
"     68,70,71",
"    </a>",
"    ]. However, over time, patients with MCI who convert to AD shift to a relatively greater preponderance of informant-reported symptoms over self-reported symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/72\">",
"     72",
"    </a>",
"    ]. This phenomenon may be helpful in following an individual patient's progression to dementia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Neuropsychiatric symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with dementia, mood and behavioral symptoms are more common in patients with MCI than in noncognitively impaired, age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/73-76\">",
"     73-76",
"    </a>",
"    ]. In one clinical trial of 1010 patients with MCI, 59 percent had behavioral problems [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/74\">",
"     74",
"    </a>",
"    ]. Depression was most prevalent (in almost half) followed by irritability, anxiety, aggression, and apathy. Patients with behavioral symptoms were significantly more impaired on cognitive measures than those without behavioral symptoms. A population-based study found that apathy, agitation, anxiety, irritability, depression, and delusions were significantly more common in patients with MCI compared with those with normal cognition [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/75\">",
"     75",
"    </a>",
"    ]. Population-based studies comparing MCI and AD patients find a similar range of neuropsychiatric symptoms, with AD patients having them in somewhat higher frequency and severity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link\">",
"     \"Treatment of behavioral symptoms related to dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between depression and cognitive impairment is complicated. Cognitive impairment may be a presenting symptom of depression, so-called pseudodementia. Depression may also be an early manifestation of cognitive impairment.",
"   </p>",
"   <p>",
"    A number of population-based studies have found an association between various measure of depression and the presence of MCI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/73,79,80\">",
"     73,79,80",
"    </a>",
"    ]. However, follow-up data has yielded somewhat mixed results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 500 85-year-old persons, impaired cognition at baseline was associated with increasing depressive symptoms over four years of follow-up, but baseline depression was not associated with accelerated cognitive decline [",
"      <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, other large cohort studies have found that depressed mood",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anxiety is associated with increased risk of MCI in patients with normal cognition, and with progression to dementia in patients with MCI [",
"      <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/73,80-83\">",
"       73,80-83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Finally, an analysis of MCI diagnostic criteria used in six clinical trials found that excluding patients with depression significantly reduced the sensitivity rates of MCI diagnosis for future AD diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the aggregate, these results appear to suggest that depression is more likely to be an early manifestation of cognitive decline rather than an independent risk factor for MCI or progression to dementia. However, other studies have found disparate results. As an example, the prospective cohort in the Religious Orders study did not exhibit an acceleration or worsening of depressive symptoms in the prodromal phase of Alzheimer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/85\">",
"     85",
"    </a>",
"    ]; similar results were reported in the Chicago Health and Aging project [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/86\">",
"     86",
"    </a>",
"    ] At the least, these studies highlight the importance of recognizing the symptoms of mood and behavioral changes in patients reporting memory problems as they may represent a group at increased risk of developing dementia, and warrant closer follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While MCI is associated with the risk of AD and other neurodegenerative dementias, other conditions can also present with mild cognitive impairment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychiatric disease, particularly depression, may present with cognitive rather than mood complaints.",
"     </li>",
"     <li>",
"      Adverse effects of medications (eg, anticholinergic, antihistamine use) and sleep disturbances are also common causes of cognitive complaints, particularly in elderly populations [",
"      <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/87,88\">",
"       87,88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Metabolic disturbances, particularly vitamin B12 deficiency and hypothyroidism, should be considered in the differential diagnosis of mild cognitive impairment (MCI).",
"     </li>",
"     <li>",
"      Normal aging can be associated with both subjective and objective cognitive changes. In general, these are not accompanied by loss of functional abilities in daily life.",
"     </li>",
"     <li>",
"      Structural brain disease is an uncommon cause of MCI in the absence of focal neurologic findings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one community sample, patients with \"cognitive impairment, no dementia\" were diagnosed with depression and other psychiatric disease (10.2 percent), alcohol and drug related causes (6.9 percent), and delirium (1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/28\">",
"     28",
"    </a>",
"    ]. Approximately one-quarter of cases had neurologic disease (brain tumor, Parkinson disease, multiple sclerosis, cerebrovascular disease, and epilepsy). Among the remaining 57.5 percent, most (31.7 percent) had circumscribed memory impairment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of patients who present with cognitive complaints is focused on establishing the severity of the impairments and providing a baseline for follow-up. Despite the high rate of progression from MCI to dementia, the absence of an established treatment limits the value of early detection and routine monitoring for progression to dementia. Nonetheless, this can be valuable for proactive decision making on the part of individual patients and family members.",
"   </p>",
"   <p>",
"    Treatable conditions should also be excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Office evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cornerstone of any evaluation of someone with memory loss is the clinical interview. Ideally, an informant will be available, and if not, attempts should be made to contact one. By discussing current events involving a variety of topics, it is often possible to develop a sense of the degree of amnestic problems. Discussing premorbid and current financial competence with patients and family members can be another useful measure of cognitive status that may be particularly sensitive to early decline [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/89\">",
"     89",
"    </a>",
"    ]. A drop-off in personal care and activities of daily living may be a later, but more specific finding, for early dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A brief, comprehensive, evaluation of the patient's cognitive profile can be performed with a number of different screening exams including the Folstein Mini-Mental State exam (MMSE), the Kokmen Short Test of Mental Status and the Montreal Cognitive Assessment (MoCA) with varying sensitivities and specificities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/91-93\">",
"     91-93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A comprehensive medical and neurologic exam must be performed to identify sources of nondegenerative causes of cognitive change.",
"   </p>",
"   <p>",
"    Underlying psychiatric conditions should also be probed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39514?source=see_link&amp;anchor=H22#H22\">",
"     \"Diagnosis and management of late-life depression\", section on 'Screening instruments'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Neuropsychological testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Quality Standards Subcommittee of the American Academy of Neurology has provided practice parameters, including evaluation guidelines for MCI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/6\">",
"     6",
"    </a>",
"    ]. Neuropsychological testing and screening cognitive evaluations (eg, mini mental status examination) are recommended to evaluate patients with suspected cognitive impairment.",
"   </p>",
"   <p>",
"    Neuropsychological testing includes an objective measure of memory impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/5\">",
"     5",
"    </a>",
"    ]. It may also have additional value in the detection of contributing or causative depression.",
"   </p>",
"   <p>",
"    Neuropsychological testing should not be used in isolation; clinical judgment is critical to diagnosing both Alzheimer disease (AD) and MCI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/10,70\">",
"     10,70",
"    </a>",
"    ]. There are no uniformly accepted criteria for the diagnosis of MCI using neuropsychological testing. Some suggest a 1.5 standard deviation (SD) threshold value for tests of memory impairment; others have used 1 SD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/1,4,29,94\">",
"     1,4,29,94",
"    </a>",
"    ]. In amnestic MCI, other cognitive domains may be impaired, but test abnormalities are generally milder and are usually within 0.5 SD of appropriate comparison groups. In multiple-domain MCI, several cognitive domains may be impaired in the 0.5 to 1.0 SD range. These ranges are not used as cutoff scores, but they provide a sense of the impairments seen in MCI.",
"   </p>",
"   <p>",
"    Other rating scales have been used to define MCI but not with uniform acceptance. These include the Clinical Dementia Rating scale (CDR) (",
"    <a class=\"graphic graphic_table graphicRef53706 \" href=\"UTD.htm?0/0/2\">",
"     table 1",
"    </a>",
"    ) and the Mini-Mental State Examination (MMSE). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of cognitive impairment and dementia\", section on 'Mini-Mental State Examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link&amp;anchor=H9#H9\">",
"     \"Evaluation of cognitive impairment and dementia\", section on 'Clinical Dementia Rating'",
"    </a>",
"    .) A CDR score of 0.5 and a score of",
"    <span class=\"nowrap\">",
"     24/30",
"    </span>",
"    on the MMSE have been used by some investigators to define MCI or CIND. However, one study found that a CDR score of 0.5 was discordant with an MCI diagnosis based on neuropsychologic test scores in 37 percent of individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/95\">",
"     95",
"    </a>",
"    ]. Individuals diagnosed with MCI based on CDR score had a lower rate of conversion to dementia than those meeting neuropsychologic test criteria, suggesting that CDR criteria are relatively nonspecific. One case series suggested that the CDR subscore in activities of daily living may be more useful than the global CDR score in indentifying individuals with MCI at risk for dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/90\">",
"     90",
"    </a>",
"    ]. An informant-based questionnaire of cognitive decline may also provide relevant information regarding the diagnosis and prognosis of MCI, but this needs further validation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who meet criteria for MCI or have persistent cognitive complaints, it is recommended that the patient return for neuropsychological reassessment in approximately one year to monitor cognitive and functional decline [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/6\">",
"     6",
"    </a>",
"    ]. Improved performance on the examination argues against neurodegenerative disease, while declining performance supports that diagnosis, even before a threshold level for dementia has been reached [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27161/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26138?source=see_link&amp;anchor=H2#H2\">",
"     \"Mild cognitive impairment: Prognosis and treatment\", section on 'Progression to dementia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26138?source=see_link&amp;anchor=H6#H6\">",
"     \"Mild cognitive impairment: Prognosis and treatment\", section on 'Neuropsychological testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of neuroimaging in the evaluation of MCI is uncertain at present.",
"   </p>",
"   <p>",
"    Most would advocate that a noncontrast brain CT should at least be performed to evaluate for cerebrovascular disease, subdural hematoma, normal pressure hydrocephalus, or mass lesion.",
"   </p>",
"   <p>",
"    Whether a magnetic resonance imaging study (MRI) should substitute for a CT scan in this setting is less certain. While MRI is more sensitive than CT, lesions causing clinically significant cognitive deficits should be visible on CT. However, MRI is more reliable than CT in assessing focal patterns of atrophy, such as temporal lobe volume loss; this latter finding may indicate an individual at particular high risk of converting from MCI to dementia. We typically order an MRI with coronal slices to image the hippocampus in our patients with MCI.",
"   </p>",
"   <p>",
"    The role of other neuroimaging tests, including positron emission tomography, functional MRI, and single photon emission CT (SPECT) in assessing the risk for and type of neurodegenerative dementia is investigational.",
"   </p>",
"   <p>",
"    The predictive value of neuroimaging tests in prognosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26138?source=see_link&amp;anchor=H11#H11\">",
"     \"Mild cognitive impairment: Prognosis and treatment\", section on 'Neuroimaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatable conditions should also be ruled out. In general, the evaluation of patients with MCI should be similar to that performed in patients presenting with dementia and include a neuroimaging study (brain CT or MRI) and screening for B12 deficiency and hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ongoing investigations are examining the relationship between apoE genotype",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the levels of certain biomarkers within the cerebrospinal fluid and the risk of converting from MCI to dementia. At the present time, there is no clinical imperative for these tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26138?source=see_link&amp;anchor=H4#H4\">",
"     \"Mild cognitive impairment: Prognosis and treatment\", section on 'Predictors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/3/31793?source=see_link\">",
"       \"Patient information: Evaluating memory and thinking problems (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/20/2370?source=see_link\">",
"       \"Patient information: Mild cognitive impairment (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=see_link\">",
"       \"Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild cognitive impairment (MCI) represents a state between normal aging and dementia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MCI includes patients with cognitive deficits that are insufficiently severe to meet criteria for dementia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Types of MCI based on the affected cognitive domains (amnestic MCI, nonamnestic MCI) are individually recognized with subtypes of single and multiple domain classifications. These clinical subtypes are believed to have value in predicting conversion to a specific type of dementia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pathologic studies of individuals with MCI generally reveal pathology of neurodegenerative or cerebrovascular disease that is intermediate between cognitively normal and demented adults. Alzheimer-type pathology typically predominates, particularly among those with amnestic MCI. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians should consider potentially treatable causes of cognitive impairment, such as psychiatric disease, the effects of medications, and underlying medical conditions. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Office evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Other testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend neuropsychological testing in individuals suspected of having MCI. Those meeting criteria for MCI and those with prominent subjective complaints should have follow-up testing to evaluate for progression between one and two years after the initial assessment. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Neuropsychological testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition, a number of screening mental status scales can be performed during office examinations for evidence of cognitive decline. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Office evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend a brain magnetic resonance imaging (MRI) study be performed in individuals with MCI to exclude structural disease and assess the extent of cerebrovascular disease and regional atrophy. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/1\">",
"      Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/2\">",
"      Bischkopf J, Busse A, Angermeyer MC. Mild cognitive impairment--a review of prevalence, incidence and outcome according to current approaches. Acta Psychiatr Scand 2002; 106:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/3\">",
"      Voisin T, Touchon J, Vellas B. Mild cognitive impairment: a nosological entity? Curr Opin Neurol 2003; 16 Suppl 2:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/4\">",
"      Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology 2004; 63:115.",
"     </a>",
"    </li>",
"    <li>",
"     Petersen, RC. Conceptual overview. In: Mild Cognitive Impairment: Aging to Alzheimer's Disease, Petersen, RC (Ed), Oxford University Press, New York 2003. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/6\">",
"      Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/7\">",
"      Salmon D, Hodges JR. Introduction: mild cognitive impairment--cognitive, behavioral, and biological factors. Neurocase 2005; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/8\">",
"      Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/9\">",
"      Busse A, Hensel A, G&uuml;hne U, et al. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 2006; 67:2176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/10\">",
"      Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology 2001; 56:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/11\">",
"      Fisk JD, Merry HR, Rockwood K. Variations in case definition affect prevalence but not outcomes of mild cognitive impairment. Neurology 2003; 61:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/12\">",
"      Mitchell AJ. Is it time to separate subjective cognitive complaints from the diagnosis of mild cognitive impairment? Age Ageing 2008; 37:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/13\">",
"      Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001; 58:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/14\">",
"      Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol 2009; 66:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/15\">",
"      Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008; 30:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/16\">",
"      Bozoki A, Giordani B, Heidebrink JL, et al. Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch Neurol 2001; 58:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/17\">",
"      DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003; 2:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/18\">",
"      Nordlund A, Rolstad S, Hellstr&ouml;m P, et al. The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry 2005; 76:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/19\">",
"      Rasquin SM, Lodder J, Visser PJ, et al. Predictive accuracy of MCI subtypes for Alzheimer's disease and vascular dementia in subjects with mild cognitive impairment: a 2-year follow-up study. Dement Geriatr Cogn Disord 2005; 19:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/20\">",
"      Alexopoulos P, Grimmer T, Perneczky R, et al. Progression to dementia in clinical subtypes of mild cognitive impairment. Dement Geriatr Cogn Disord 2006; 22:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/21\">",
"      Matthews FE, Stephan BC, McKeith IG, et al. Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree? J Am Geriatr Soc 2008; 56:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/22\">",
"      Taragano FE, Allegri RF, Krupitzki H, et al. Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. J Clin Psychiatry 2009; 70:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/23\">",
"      Kwong LK, Neumann M, Sampathu DM, et al. TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol 2007; 114:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/24\">",
"      Molano J, Boeve B, Ferman T, et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain 2010; 133:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/25\">",
"      Stokholm J, Jakobsen O, Czarna JM, et al. Years of severe and isolated amnesia can precede the development of dementia in early-onset Alzheimer's disease. Neurocase 2005; 11:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/26\">",
"      Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer's disease. Nat Med 2004; 10 Suppl:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/27\">",
"      Ritchie K, Touchon J. Mild cognitive impairment: conceptual basis and current nosological status. Lancet 2000; 355:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/28\">",
"      Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997; 349:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/29\">",
"      Crook, TH, Bartus, RT, Ferris, SH, et al. Age-associated memory impairment: proposed diagnostic creiteria measures clinical change - report of a National Institute of Mental Health Work Group. Dev Neuropsychol 1986; 2:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/30\">",
"      Levy R. Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatr 1994; 6:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/31\">",
"      Richards M, Touchon J, Ledesert B, Richie K. Cognitive decline in ageing: are AAMI and AACD distinct entities? Int J Geriatr Psychiatry 1999; 14:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/32\">",
"      Small BJ, Mobly JL, Laukka EJ, et al. Cognitive deficits in preclinical Alzheimer's disease. Acta Neurol Scand Suppl 2003; 179:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/33\">",
"      Larrieu S, Letenneur L, Orgogozo JM, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002; 59:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/34\">",
"      Tschanz JT, Welsh-Bohmer KA, Lyketsos CG, et al. Conversion to dementia from mild cognitive disorder: the Cache County Study. Neurology 2006; 67:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/35\">",
"      Busse A, Bischkopf J, Riedel-Heller SG, et al. Mild cognitive impairment: prevalence and predictive validity according to current approaches. Acta Neurol Scand 2003; 108:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/36\">",
"      Luck T, Riedel-Heller SG, Kaduszkiewicz H, et al. Mild cognitive impairment in general practice: age-specific prevalence and correlate results from the German study on ageing, cognition and dementia in primary care patients (AgeCoDe). Dement Geriatr Cogn Disord 2007; 24:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/37\">",
"      Lopez OL, Jagust WJ, DeKosky ST, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol 2003; 60:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/38\">",
"      Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med 2008; 148:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/39\">",
"      Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology 2010; 75:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/40\">",
"      Manly JJ, Tang MX, Schupf N, et al. Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol 2008; 63:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/41\">",
"      Caracciolo B, Palmer K, Monastero R, et al. Occurrence of cognitive impairment and dementia in the community: a 9-year-long prospective study. Neurology 2008; 70:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/42\">",
"      Luck T, Luppa M, Briel S, et al. Mild cognitive impairment: incidence and risk factors: results of the leipzig longitudinal study of the aged. J Am Geriatr Soc 2010; 58:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/43\">",
"      Luck T, Luppa M, Briel S, Riedel-Heller SG. Incidence of mild cognitive impairment: a systematic review. Dement Geriatr Cogn Disord 2010; 29:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/44\">",
"      Plassman BL, Langa KM, McCammon RJ, et al. Incidence of dementia and cognitive impairment, not dementia in the United States. Ann Neurol 2011; 70:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/45\">",
"      Manly JJ, Bell-McGinty S, Tang MX, et al. Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community. Arch Neurol 2005; 62:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/46\">",
"      Kryscio RJ, Schmitt FA, Salazar JC, et al. Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology 2006; 66:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/47\">",
"      Das SK, Bose P, Biswas A, et al. An epidemiologic study of mild cognitive impairment in Kolkata, India. Neurology 2007; 68:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/48\">",
"      Tyas SL, Salazar JC, Snowdon DA, et al. Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. Am J Epidemiol 2007; 165:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/49\">",
"      DeCarli C, Miller BL, Swan GE, et al. Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol 2001; 58:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/50\">",
"      Luchsinger JA, Reitz C, Patel B, et al. Relation of diabetes to mild cognitive impairment. Arch Neurol 2007; 64:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/51\">",
"      Reitz C, Tang MX, Manly J, et al. Hypertension and the risk of mild cognitive impairment. Arch Neurol 2007; 64:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/52\">",
"      Roberts RO, Geda YE, Knopman DS, et al. Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol 2008; 65:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/53\">",
"      Schultz MR, Lyons MJ, Franz CE, et al. Apolipoprotein E genotype and memory in the sixth decade of life. Neurology 2008; 70:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/54\">",
"      Farlow MR, He Y, Tekin S, et al. Impact of APOE in mild cognitive impairment. Neurology 2004; 63:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/55\">",
"      Boyle PA, Buchman AS, Wilson RS, et al. The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons. Neuroepidemiology 2010; 34:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/56\">",
"      Bennett DA, Schneider JA, Bienias JL, et al. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005; 64:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/57\">",
"      Petersen RC, Parisi JE, Dickson DW, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006; 63:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/58\">",
"      Sabbagh MN, Shah F, Reid RT, et al. Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. Arch Neurol 2006; 63:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/59\">",
"      Davis KL, Mohs RC, Marin D, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999; 281:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/60\">",
"      DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002; 51:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/61\">",
"      Markesbery WR, Schmitt FA, Kryscio RJ, et al. Neuropathologic substrate of mild cognitive impairment. Arch Neurol 2006; 63:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/62\">",
"      Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 2003; 60:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/63\">",
"      Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006; 63:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/64\">",
"      Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009; 66:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/65\">",
"      Wilson RS, Leurgans SE, Boyle PA, et al. Neurodegenerative basis of age-related cognitive decline. Neurology 2010; 75:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/66\">",
"      Tobiansky R, Blizard R, Livingston G, Mann A. The Gospel Oak Study stage IV: the clinical relevance of subjective memory impairment in older people. Psychol Med 1995; 25:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/67\">",
"      Geerlings MI, Jonker C, Bouter LM, et al. Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. Am J Psychiatry 1999; 156:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/68\">",
"      van Norden AG, Fick WF, de Laat KF, et al. Subjective cognitive failures and hippocampal volume in elderly with white matter lesions. Neurology 2008; 71:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/69\">",
"      Riedel-Heller SG, Matschinger H, Schork A, Angermeyer MC. Do memory complaints indicate the presence of cognitive impairment? Results of a field study. Eur Arch Psychiatry Clin Neurosci 1999; 249:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/70\">",
"      Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/71\">",
"      Stewart R, Dufouil C, Godin O, et al. Neuroimaging correlates of subjective memory deficits in a community population. Neurology 2008; 70:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/72\">",
"      Tabert MH, Albert SM, Borukhova-Milov L, et al. Functional deficits in patients with mild cognitive impairment: prediction of AD. Neurology 2002; 58:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/73\">",
"      Palmer K, Berger AK, Monastero R, et al. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology 2007; 68:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/74\">",
"      Feldman H, Scheltens P, Scarpini E, et al. Behavioral symptoms in mild cognitive impairment. Neurology 2004; 62:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/75\">",
"      Geda YE, Roberts RO, Knopman DS, et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry 2008; 65:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/76\">",
"      Okura T, Plassman BL, Steffens DC, et al. Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study. J Am Geriatr Soc 2010; 58:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/77\">",
"      Lopez OL, Becker JT, Sweet RA. Non-cognitive symptoms in mild cognitive impairment subjects. Neurocase 2005; 11:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/78\">",
"      Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002; 288:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/79\">",
"      Vinkers DJ, Gussekloo J, Stek ML, et al. Temporal relation between depression and cognitive impairment in old age: prospective population based study. BMJ 2004; 329:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/80\">",
"      Wilson RS, Schneider JA, Boyle PA, et al. Chronic distress and incidence of mild cognitive impairment. Neurology 2007; 68:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/81\">",
"      Geda YE, Knopman DS, Mrazek DA, et al. Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch Neurol 2006; 63:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/82\">",
"      Goveas JS, Espeland MA, Woods NF, et al. Depressive symptoms and incidence of mild cognitive impairment and probable dementia in elderly women: the Women's Health Initiative Memory Study. J Am Geriatr Soc 2011; 59:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/83\">",
"      Caracciolo B, B&auml;ckman L, Monastero R, et al. The symptom of low mood in the prodromal stage of mild cognitive impairment and dementia: a cohort study of a community dwelling elderly population. J Neurol Neurosurg Psychiatry 2011; 82:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/84\">",
"      Visser PJ, Scheltens P, Verhey FR. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? J Neurol Neurosurg Psychiatry 2005; 76:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/85\">",
"      Wilson RS, Arnold SE, Beck TL, et al. Change in depressive symptoms during the prodromal phase of Alzheimer disease. Arch Gen Psychiatry 2008; 65:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/86\">",
"      Wilson RS, Hoganson GM, Rajan KB, et al. Temporal course of depressive symptoms during the development of Alzheimer disease. Neurology 2010; 75:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/87\">",
"      Boustani M, Hall KS, Lane KA, et al. The association between cognition and histamine-2 receptor antagonists in African Americans. J Am Geriatr Soc 2007; 55:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/88\">",
"      Carri&egrave;re I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med 2009; 169:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/89\">",
"      Triebel KL, Martin R, Griffith HR, et al. Declining financial capacity in mild cognitive impairment: A 1-year longitudinal study. Neurology 2009; 73:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/90\">",
"      Chang YL, Bondi MW, McEvoy LK, et al. Global clinical dementia rating of 0.5 in MCI masks variability related to level of function. Neurology 2011; 76:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/91\">",
"      Folstein MF, Folstein SE, McHugh PR. \"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/92\">",
"      Kokmen E, Smith GE, Petersen RC, et al. The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol 1991; 48:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/93\">",
"      Nasreddine ZS, Phillips NA, B&eacute;dirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/94\">",
"      Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/95\">",
"      Saxton J, Snitz BE, Lopez OL, et al. Functional and cognitive criteria produce different rates of mild cognitive impairment and conversion to dementia. J Neurol Neurosurg Psychiatry 2009; 80:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27161/abstract/96\">",
"      Isella V, Villa L, Russo A, et al. Discriminative and predictive power of an informant report in mild cognitive impairment. J Neurol Neurosurg Psychiatry 2006; 77:166.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5081 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_33_27161=[""].join("\n");
var outline_f26_33_27161=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25688360\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Amnestic MCI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Single domain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Multiple domains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Non-amnestic MCI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Single domain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Multiple domains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Related terminology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cognitive complaints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Neuropsychiatric symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Office evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Neuropsychological testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5081\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5081|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/0/2\" title=\"table 1\">",
"      Clinical dementia rating",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=related_link\">",
"      Clinical manifestations and diagnosis of Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39514?source=related_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26138?source=related_link\">",
"      Mild cognitive impairment: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/3/31793?source=related_link\">",
"      Patient information: Evaluating memory and thinking problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/20/2370?source=related_link\">",
"      Patient information: Mild cognitive impairment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41369?source=related_link\">",
"      Prevention of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=related_link\">",
"      Risk factors for dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=related_link\">",
"      Treatment of dementia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_33_27162="Clinical manifestations and diagnosis of Alzheimer disease";
var content_f26_33_27162=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of Alzheimer disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/33/27162/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27162/contributors\">",
"     Thomas J Grabowski, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/33/27162/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27162/contributors\">",
"     Steven T DeKosky, MD, FAAN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/33/27162/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/33/27162/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/33/27162/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alzheimer disease (AD) is a neurodegenerative disorder of uncertain cause and pathogenesis that primarily affects older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/1\">",
"     1",
"    </a>",
"    ]. The main clinical manifestations of AD are selective memory impairment and dementia. AD is the most common cause of dementia. While treatments are available that can modulate the course of the disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ameliorate some symptoms, there is no cure, and the disease inevitably progresses in all patients.",
"   </p>",
"   <p>",
"    This topic reviews the clinical manifestations and diagnosis of AD. Other topics review the risk factors and treatment of AD and the clinical manifestations of other causes of dementia and cognitive impairment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=see_link\">",
"     \"Risk factors for dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=see_link\">",
"     \"Treatment of dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1913?source=see_link\">",
"     \"Cholinesterase inhibitors in the treatment of dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27161?source=see_link\">",
"     \"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=see_link\">",
"     \"Clinical features and diagnosis of dementia with Lewy bodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of vascular dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEMOGRAPHIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alzheimer disease (AD) is characteristically a disease of older age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/2\">",
"     2",
"    </a>",
"    ]. It is exceptional for AD to occur before age 60. The incidence and prevalence of AD increase exponentially with age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=see_link&amp;anchor=H2#H2\">",
"     \"Risk factors for dementia\", section on 'Age'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AD is slightly more common in women than men, with a relative risk of 1.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/3\">",
"     3",
"    </a>",
"    ]. This does not appear to be explained by the greater longevity in women.",
"   </p>",
"   <p>",
"    There are inherited forms of AD, all autosomal dominant, that routinely present before age 65, and frequently in the fifth decade or earlier. These account for less than 5 percent of all cases of AD. Patients with Down syndrome develop AD at an earlier age, 10 to 20 years younger than the general population with AD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=see_link&amp;anchor=H4#H4\">",
"     \"Risk factors for dementia\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other risk categories for AD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=see_link\">",
"     \"Risk factors for dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Memory impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Memory impairment is an essential feature of AD and is often its earliest manifestation. Even when not the primary complaint, memory deficits can be elicited in most patients with AD at the time of presentation.",
"   </p>",
"   <p>",
"    The pattern of memory impairment in AD is also distinctive [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/5\">",
"     5",
"    </a>",
"    ]. Declarative memory for facts and events, which depend on mesial temporal and neocortical structures are profoundly affected in AD, while subcortical systems supporting procedural memory and motor learning are relatively spared until quite late in the disease. A subset of declarative memory, that of specific events and contexts (episodic memory) is more profoundly impaired in early AD, compared with memory for facts such as vocabulary and concepts (semantic memory), which often becomes impaired somewhat later. Semantic memory is encoded in neocortical (nonmesial) temporal regions.",
"   </p>",
"   <p>",
"    Within episodic memory, there is a distinction between immediate recall (eg, mental rehearsal of a phone number), memory for recent events (which comes into play once material that has departed from consciousness must be recalled), and memory of more distant events. Memory for recent events, served by the hippocampus, entorhinal cortex, and related structures in the mesial temporal lobe, is prominently impaired in early AD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In contrast, immediate memory (encoded in the sensory association and prefrontal cortices) is spared early on, as are memories that are consolidated for long periods of time (years), which can be recalled without hippocampal function.",
"   </p>",
"   <p>",
"    The early memory deficit in AD is most precisely described as anterograde long-term episodic amnesia. Because the absolute time interval over which long-term memory can fail can actually be short (eg, inability to recall a few words after a couple minutes of distraction), patients and caregivers typically refer to \"short-term memory\" problems. For this reason, we try to avoid the confusion afforded by the technical terms of long-term and short-term memory and use the term \"recent memory impairment\" to refer to the characteristic impairment.",
"   </p>",
"   <p>",
"    Memory deficits develop insidiously and progress slowly over time, evolving to include deficits of semantic memory and immediate recall. Impairments of procedural memory appear only in late stages of AD.",
"   </p>",
"   <p>",
"    Memory is usually tested by asking patients to recall three objects immediately and then at a delay of 5 to 10 minutes. Impaired ability to recall objects with selective cues (hints) represents a more severe deficit and one that may be particularly specific for AD in its early presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/9\">",
"     9",
"    </a>",
"    ]. Questions about orientation and recent current events are also useful memory tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23303?source=see_link&amp;anchor=H28388614#H28388614\">",
"     \"The mental status examination in adults\", section on 'Memory'",
"    </a>",
"    .) Clinicians should not rely on a patient's report of memory impairment, as many older individuals are unreliable reporters of their own memory impairment and can both over and under estimate their deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Amnestic mild cognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A state of circumscribed anterograde long-term memory impairment, with preserved general cognitive, social functioning is known as amnestic mild cognitive impairment (MCI) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/11\">",
"     11",
"    </a>",
"    ]. Amnestic MCI is increasingly recognized as an early stage of AD, with a conversion rate to dementia at about 10 to 15 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27161?source=see_link&amp;anchor=H3#H3\">",
"     \"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment\", section on 'Amnestic MCI'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26138?source=see_link&amp;anchor=H2#H2\">",
"     \"Mild cognitive impairment: Prognosis and treatment\", section on 'Progression to dementia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Formal clinical diagnostic criteria for MCI due to AD have recently been developed by a panel convened by the National Institute on Aging and The Alzheimer Association [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/13\">",
"     13",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A concern regarding cognition reported by the patient or informant or observed by clinician",
"     </li>",
"     <li>",
"      Objective evidence of impairment in one or more cognitive domains that is not explained by age or education",
"     </li>",
"     <li>",
"      Preservation of independence in functional abilities",
"     </li>",
"     <li>",
"      Not demented",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other aspects of cognitive decline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficits in other cognitive domains may appear with or after the development of memory impairment. Language function and visuospatial skills tend to be affected relatively early, while deficits in executive function and behavioral symptoms often manifest later in the disease course. These deficits appear and progress insidiously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Language",
"    </span>",
"    &nbsp;&mdash;&nbsp;Verbal disfluency and anomia are often early features of AD and are sometimes the presenting feature [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/14\">",
"     14",
"    </a>",
"    ]. The first manifestations of language dysfunction usually include word-finding difficulties, circumlocution, and reduced vocabulary in spontaneous speech and anomia on confrontational naming tests. This progresses to include agrammatism, paraphasic errors, impoverished speech content, and impaired comprehension. Patients can usually repeat phrases verbatim until the disease is quite advanced. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20041?source=see_link&amp;anchor=H6#H6\">",
"     \"Approach to the patient with aphasia\", section on 'Clinical assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Language dysfunction and loss of semantic memory are interrelated in AD. Some investigators have found that loss of semantic fluency is an early finding in AD. When asked to generate word lists in one minute's time, patients with AD perform significantly worse on a category fluency test (eg, lists of animals) than on a letter fluency test (eg, lists of words beginning with F) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Normal performance is age related, with at least 15 items expected at age 65 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Visuospatial skills",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of visuospatial skills is an early feature of AD that is sometimes very prominent at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Visuospatial impairments manifest as misplacement of items and difficulty navigating in first unfamiliar then familiar terrain. Visual agnosia (inability to recognize objects) and prosopagnosia (inability to recognize faces) are later features. Some clinicians have noted hemispatial visual neglect in their patients with AD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Visuospatial skills may be tested by asking patients to copy elementary figures (eg, intersecting pentagons) and to draw a clock face. The latter, when combined with a request to fill in the time at \"ten after eleven,\" is a deceptively difficult test and evaluates semantic knowledge as well as executive and spatial functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Insight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced insight into his or her deficits (anosognosia) is a characteristic feature of AD and has been linked to frontal lobe pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. It is common for patients to underestimate their deficits and offer alibis or explanations for them when they are pointed out. Interviewing a collateral historian, usually a family member, who has known the patient over time, is helpful, and often it is the family member, not the patient, who brings the complaint of cognitive impairment to medical attention.",
"   </p>",
"   <p>",
"    Loss of insight increases over time along with overall disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/26\">",
"     26",
"    </a>",
"    ]. Relative loss of insight is associated with behavioral disturbances; those with relatively preserved insight are more likely to be depressed, while those with more impaired insight are likely to be agitated, disinhibited, and exhibit psychotic features [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Apraxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspraxia, or difficulty performing learned motor tasks, usually occurs later in the disease after deficits in memory and language are apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/29\">",
"     29",
"    </a>",
"    ]. Before it is clinically apparent, dyspraxia can be elicited by asking the patient to perform ideomotor tasks, ie, pantomime the use of tools (eg, \"show me how you would use a comb\") [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Clinical dyspraxia leads to progressive difficulty first with complex, multi-step motor activities, then with dressing, feeding, and other self-care tasks and is a big contributor to dependency in mid to late stages of AD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Executive function",
"    </span>",
"    &nbsp;&mdash;&nbsp;In early stages of AD, impairment in executive function may be subtle rather than frank [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/33\">",
"     33",
"    </a>",
"    ]; family members and coworkers may find them less motivated and engaged. In addition to poor insight, reduced ability for abstract reasoning may be elicited. As the disease progresses, a more manifest alteration of personality, poor judgment and planning, and an inability to complete tasks typically emerges.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Neuropsychiatric symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropsychiatric symptoms are common in AD, particularly in the middle and late course of disease. These can begin with subtle personality changes including apathy, social disengagement, and disinhibition. The former may be a manifestation of superimposed depression, which can be difficult to diagnose in the setting of dementia.",
"   </p>",
"   <p>",
"    More problematic in patient management is the emergence of behavioral disturbances, including agitation, aggression, wandering, and psychosis (hallucinations, delusions, misidentification syndromes). A concomitant medical illness, medication toxicity, and other causes of delirium should be considered whenever new behavioral disturbances arise. The behavioral disturbances associated with AD are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link\">",
"     \"Treatment of behavioral symptoms related to dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other neurologic deficits",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early stages, patients with AD generally have a normal neurologic examination except for the cognitive examination. While pyramidal and extrapyramidal motor signs, myoclonus, and seizures do occur in patients with AD, these are typically late-stage findings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/34\">",
"     34",
"    </a>",
"    ]. If these are clinically apparent in early to middle stages, an alternative diagnosis should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/35\">",
"     35",
"    </a>",
"    ]. Similarly, frontal release signs (grasp, snout reflexes, gegenhalten) and incontinence are late, rather than early, features of AD.",
"   </p>",
"   <p>",
"    Seizures occur in 9 to 16 percent of patients with AD, usually in the later stages of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. Epilepsy in the setting of AD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40841?source=see_link&amp;anchor=H12#H12\">",
"     \"Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis\", section on 'Dementia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Atypical presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of Alzheimer cases do not present in the classic fashion with progressive amnestic dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Distinguishing these cases from other causes of dementia can be challenging. Neuropathologic studies in such patients have found Alzheimer pathology with an atypical neuroanatomic distribution that corresponds with the anatomy of the most prominent clinical deficits; neuroimaging studies often have corresponding findings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/42-47\">",
"     42-47",
"    </a>",
"    ]. Some case series suggest that these atypical presentations are more common in early-onset (AD), patients who present before age 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Posterior cortical atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;This syndrome manifests with progressive cortical visual impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/18,41,45,50-54\">",
"     18,41,45,50-54",
"    </a>",
"    ]. Patients are often first evaluated by optometrists or ophthalmologists for visual complaints, such as difficulty reading and driving [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/42,52\">",
"     42,52",
"    </a>",
"    ]. Detailed neurologic evaluation may elicit elements of the Balint syndrome: simultanagnosia (the inability to integrate a visual scene despite adequate acuity to resolve individual elements); optic ataxia (the inability to reach accurately under visual guidance); and ocular apraxia (the inability to direct gaze accurately to a new target, frequently leading to difficulty reading). Other features include visual agnosia; ideomotor, constructional, and dressing apraxia; prosopagnosia; and visual field neglect. Less common are visual hallucinations and symptomatic visual field defects, although the latter are more frequently found when computer guided perimetry (as opposed to confrontational testing) is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/55\">",
"     55",
"    </a>",
"    ]. This constellation of findings implicates the dorsal visual stream in the lateral occipital and parieto-occipital regions.",
"   </p>",
"   <p>",
"    On testing, these patients usually have recent memory impairment, although it is not the most salient feature of their illness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/41\">",
"     41",
"    </a>",
"    ]. Acalculia, alexia, and anomia are also common early deficits in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/56\">",
"     56",
"    </a>",
"    ]. Insight is variably retained.",
"   </p>",
"   <p>",
"    In most patients, neuropathologic examination reveals Alzheimer pathology with an exceptional distribution involving visual association areas and even primary visual cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/42,53,57,58\">",
"     42,53,57,58",
"    </a>",
"    ]. Neuroimaging findings also usually demonstrate this neuroanatomic pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/44,56,57,59\">",
"     44,56,57,59",
"    </a>",
"    ], although in one series of 12 patients with posterior cortical atrophy, amyloid deposition on positron emission tomography demonstrated a distribution that was similar to patients with typical AD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/60\">",
"     60",
"    </a>",
"    ]. A minority of patients with this syndrome have an alternative pathology, including cortical Lewy bodies, tauopathy, and prion disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/53,57\">",
"     53,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Primary progressive aphasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive nonfluent aphasia (PNFA) is usually associated with frontotemporal dementia (FTD) rather than AD. However a significant percentage (up to one-third) are found at autopsy to have AD instead [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/41,42,44,61-63\">",
"     41,42,44,61-63",
"    </a>",
"    ]. Features suggesting FTD rather than AD include age of onset &lt;60 years, prominent behavioral symptoms, and knife-edge frontotemporal atrophy at least in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/64\">",
"     64",
"    </a>",
"    ]. Other case series have found that early memory impairment and a pattern of logopenia (frequent word-finding pauses without major grammar or comprehension deficits) suggested AD rather than FTD; however neither of these features are reliably predictive [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/14,44,63,65-67\">",
"     14,44,63,65-67",
"    </a>",
"    ]. AD pathology is also sometimes found in patients with semantic dementia, but this is less common [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link&amp;anchor=H5#H5\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\", section on 'Progressive nonfluent aphasia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link&amp;anchor=H6#H6\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\", section on 'Semantic dementia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link&amp;anchor=H12#H12\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neuroimaging and neuropathologic studies in patients with PNFA attributed to AD demonstrate most prominent involvement of the left perisylvian area [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/42,44,68\">",
"     42,44,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Biparietal syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the biparietal syndrome of AD often present with dyspraxia and have difficulty completing simple bimanual tasks, such as dressing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/41,69\">",
"     41,69",
"    </a>",
"    ]. Other early clinical features can include visuospatial disorientation, dysgraphia, and language impairment with semantic memory deficits (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Memory impairment'",
"    </a>",
"    above). Neuropathologic examination and neuroimaging studies demonstrate prominent involvement of the parietal lobes bilaterally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients with AD present with prominent deficits in executive function relative to amnesia. In one case series of 88 such patients, MRIs revealed more thinning in the frontoparietal cortical regions, the clinical course appeared to involve more rapid progression, and the prevalence of the APOE &epsilon;4 allele was lower compared to the more typical AD patients with prominent memory deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rare patients with clinical features consistent with corticobasal degeneration and the behavioral variant of frontotemporal dementia are found at postmortem to have Alzheimer pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/42,71\">",
"     42,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Mixed dementias",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not rare for Alzheimer pathology to coexist with other processes, including vascular lesions, cortical Lewy bodies, argyrophilic grain disease, and Parkinson disease. The combination of two pathologies can influence the clinical presentation and course of the disease and present diagnostic challenges [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As expected, the most common combination is that of AD and vascular dementia. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology, clinical manifestations, and diagnosis of vascular dementia\", section on 'Mixed dementia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another combination that is described is that of diffuse Lewy body and AD dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. In affected patients, prominent memory loss can coexist with one or more features of dementia with Lewy bodies, including visual hallucinations, fluctuations in sensorium, parkinsonism, and falls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=see_link\">",
"     \"Clinical features and diagnosis of dementia with Lewy bodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;AD progresses inexorably. The progress of the disease can be measured with mental status scales such as the Mini-Mental State Examination (MMSE) and the Clinical Dementia Rating Scale (",
"    <a class=\"graphic graphic_table graphicRef53706 \" href=\"UTD.htm?0/0/2\">",
"     table 1",
"    </a>",
"    ). The clinical course, as measured by such scales, is not necessarily linear, however, a number of studies have found that patients decline 3 to 3.5 points on average on the MMSE each year [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/76-79\">",
"     76-79",
"    </a>",
"    ], with a minority (&lt;10 percent) having a more rapidly progressive decline of 5 to 6 points on annual MMSE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/80\">",
"     80",
"    </a>",
"    ]. An older age of onset of AD (&gt;80 years) may be associated with a slower rate of decline compared to younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported mean survival after diagnosis of AD ranges from three to eight years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. Patients generally succumb to terminal-stage complications that relate to advanced debilitation, such as dehydration, malnutrition, and infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common disorders considered in the differential diagnosis of AD are vascular dementia and other neurodegenerative dementias.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular dementia is caused by either ischemic or hemorrhagic strokes. The most common form is due to small vessel cerebrovascular disease. Diagnosis is most specific if there is a stroke-like course of illness, neurologic signs of stroke on examination, and imaging evidence of stroke. However, the course of illness may appear smoothly progressive, and there may be no elementary neurologic signs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of vascular dementia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dementia with Lewy bodies is the second most common type of degenerative dementia after AD. Clinical features that help distinguish this from AD include prominent early appearance of visual hallucinations, along with parkinsonism, cognitive fluctuations, dysautonomia, sleep disorders, and neuroleptic sensitivity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=see_link\">",
"       \"Clinical features and diagnosis of dementia with Lewy bodies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Frontotemporal dementia (FTD) is a neuropathologically and clinically heterogeneous disorder characterized by focal degeneration of the frontal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      temporal lobes. Early alteration of personality, behavior, and executive functioning distinguish behavioral variant FTD from AD, however, it can be difficult to distinguish FTD from AD as a cause of primary progressive nonfluent aphasia, especially early in the course. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link\">",
"       \"Frontotemporal dementia: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16\">",
"       'Primary progressive aphasia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis of AD requires histopathologic examination, which is rarely done in life [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/85-87\">",
"     85-87",
"    </a>",
"    ]. The diagnosis of AD in practice depends on clinical criteria. The role of laboratory and imaging investigations is mainly to exclude other diagnoses. Neuropsychological testing may provide confirmatory information and aid in patient management.",
"   </p>",
"   <p>",
"    Clinicians should also consider potential contributors to the dementia syndrome such as adverse effects of medication, depression, and metabolic disorders and deficiencies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Clinical assessments",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical criteria are based on a history of insidious onset and progressive course, exclusion of other etiologies, and documentation of cognitive impairments in one or more domains. A detailed cognitive and general neurologic examination is paramount. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Many clinicians make use of standardized mental status scales, in particular, the Mini-Mental State Examination (MMSE), to document the presence and progression of dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. It is important to use population-appropriate reference scores in the MMSE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/90\">",
"     90",
"    </a>",
"    ]. The administration of this test is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of cognitive impairment and dementia\", section on 'Mini-Mental State Examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A MMSE score between 20 and 26 is associated with mild functional dependence, such as difficulty managing finances. Moderate AD (MMSE score between 10 and 20) is associated with more immediate dependency, such as inability to drive, difficulty with hygiene and shopping, and remote memory impairment. Severe disease (MMSE score under 10) correlates with a state of total dependence and need for constant supervision. Motor impairments, notably gait and balance impairment, incontinence, and myoclonus, develop at this late stage, and presage total debility. Some third-party payers require documentation of MMSE to support specific pharmacologic interventions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=see_link\">",
"     \"Treatment of dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Clinical criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria for the diagnosis of probable AD dementia have been established by the National Institute on Aging and The Alzheimer's Association [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/35,91\">",
"     35,91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Probable AD dementia is a syndrome of dementia defined by the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interference with ability to function at work or at usual activities",
"     </li>",
"     <li>",
"      A decline from a previous level of functioning and performing",
"     </li>",
"     <li>",
"      Not explained by delirium or major psychiatric disorder",
"     </li>",
"     <li>",
"      Cognitive impairment established by history-taking from the patient",
"      <em>",
"       and",
"      </em>",
"      a knowledgeable informant; and objective bedside mental status examination or neuropsychological testing",
"     </li>",
"     <li>",
"      Cognitive impairment involving a minimum of two of the following domains:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      impaired ability to acquire and remember new information",
"     </li>",
"     <li>",
"      impaired reasoning and handing of complex tasks, poor judgment",
"     </li>",
"     <li>",
"      impaired visuospatial abilities",
"     </li>",
"     <li>",
"      impaired language functions",
"     </li>",
"     <li>",
"      changes in personality, behavior or comportment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other core clinical criteria include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insidious onset",
"     </li>",
"     <li>",
"      Clear-cut history of worsening",
"     </li>",
"     <li>",
"      Initial and most prominent cognitive deficits are one of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      amnestic presentation",
"     </li>",
"     <li>",
"      nonamnestic presentations include either a language presentation, with prominent word-finding deficits; a visuospatial presentation, with visual cognitive deficits; or a dysexecutive presentation, with prominent impairment of reasoning, judgment",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      problem solving",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No evidence of substantial concomitant cerebrovascular disease, core features of dementia with Lewy bodies, prominent features of behavioral variant frontotemporal dementia or prominent features of semantic or",
"    <span class=\"nowrap\">",
"     nonfluent/agrammatic",
"    </span>",
"    variants of primary progressive aphasia, or evidence of another concurrent, active neurologic or non-neurologic disease or use of medication that could have a substantial effect on cognition.",
"   </p>",
"   <p>",
"    Possible AD includes the following clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atypical onset, presentation, or progression of dementia without known etiology",
"     </li>",
"     <li>",
"      Presence of another potentially causative systemic or neurologic disorder that is not thought to be the etiology of dementia in this case",
"     </li>",
"     <li>",
"      Progressive deterioration in a single cognitive domain in the absence of any other etiology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria are based on and are more restrictive than the 1984 NIDCD-ADRDA criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/35\">",
"     35",
"    </a>",
"    ]; all patients who met criteria by the older criteria would meet the current criteria. The older criteria were confirmed at autopsy in dementia research centers in 85 to 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The DSM-IV TR criteria for AD are also commonly used [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/94\">",
"     94",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The development of multiple cognitive deficits manifested by both:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Memory impairment",
"     </li>",
"     <li>",
"      One or more of the following cognitive disturbances: aphasia, apraxia, agnosia, disturbance in executive functioning",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cognitive deficits cause significant impairment in social or occupational functioning and represent a significant decline from a previous level of functioning",
"     </li>",
"     <li>",
"      The course is characterized by gradual onset and continuing decline",
"     </li>",
"     <li>",
"      The deficits are not due to another brain, systemic, or psychiatric condition",
"     </li>",
"     <li>",
"      The deficits do not occur exclusively during the course of delirium",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While less substantially validated compared with the NINCDS-ADRDA criteria, the DSM-IV criteria appear to have similar accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/95,96\">",
"     95,96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain imaging, preferably with magnetic resonance imaging (MRI), is indicated in the evaluation of patients with suspected AD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/96\">",
"     96",
"    </a>",
"    ]. Brain MRI can document potential alternative diagnoses including cerebrovascular disease, other structural diseases (chronic subdural hematoma, cerebral neoplasm, normal pressure hydrocephalus), and regional brain atrophy suggesting frontotemporal dementia.",
"   </p>",
"   <p>",
"    MRI findings in AD include both generalized and focal atrophy, as well as white matter lesions. In general, these findings are nonspecific. However, a number of investigators have correlated reduced hippocampal volume with AD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/46,97-100\">",
"     46,97-100",
"    </a>",
"    ]. Because hippocampal volumes decline in normal aging, age-specific criteria are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/97,98,101\">",
"     97,98,101",
"    </a>",
"    ]. It is not clear that this finding adds to the accuracy of the diagnosis over the clinical assessment alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/102\">",
"     102",
"    </a>",
"    ]. Some studies have suggested that MRI features may predict rate of decline of AD and in the future may guide treatment decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/77,103\">",
"     77,103",
"    </a>",
"    ]. However, these findings require independent confirmation.",
"   </p>",
"   <p>",
"    Functional brain imaging with [18F] fluorodeoxyglucose positron emission tomography (FDG-PET), functional MRI (fMRI), perfusion MRI, or perfusion single photon emission computed tomography (SPECT) reveals distinct regions of low metabolism and hypoperfusion in AD. These areas include the hippocampus, the precuneus (mesial parietal lobes) and the lateral parietotemporal cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/8,104-109\">",
"     8,104-109",
"    </a>",
"    ]. Clinical studies suggest that FDG-PET may be useful in distinguishing AD from frontotemporal dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/110-113\">",
"     110-113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amyloid PET tracers (eg, 11C-labeled Pittsburgh compound-B,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/60/19395?source=see_link\">",
"     Florbetapir F18",
"    </a>",
"    , and others) that measure amyloid lesion burden in the brain have been recently developed more recently and are under investigation as a tool to positively diagnose AD in vivo, aid in prognosis, and differentiate AD from other causes of dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/113-133\">",
"     113-133",
"    </a>",
"    ]. Florbetapir F18 has been approved by the U.S. Food and Drug Administration for this purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/134\">",
"     134",
"    </a>",
"    ]; While this information may add value to the clinical assessment, these technologies are not universally available, and are not part of the routine assessment of patients with AD, in part because there is no clear therapeutic imperative to distinguish among the neurodegenerative dementias [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/135,136\">",
"     135,136",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests are not useful in the positive diagnosis of Alzheimer disease; however, some laboratory tests are indicated to exclude contributing secondary causes. Recommended tests include screening for hypothyroidism and vitamin B12 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/96\">",
"     96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies suggest that certain biomarkers including increased levels of tau protein and decreased levels of beta-amyloid protein ending at amino acid 42 in cerebrospinal fluid (CSF) or plasma, elevated apoE and apoE4 plasma levels, and others may have predictive value for AD in nondemented patients and in patients with MCI, may also distinguish AD from other forms of dementia, and may identify subsets of patients with AD at risk for a rapidly progressive course [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/137-166\">",
"     137-166",
"    </a>",
"    ]. &nbsp;However, a role for these measurements in clinical practice has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/167-170\">",
"     167-170",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26138?source=see_link&amp;anchor=H9#H9\">",
"     \"Mild cognitive impairment: Prognosis and treatment\", section on 'CSF biomarkers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26138?source=see_link&amp;anchor=H10#H10\">",
"     \"Mild cognitive impairment: Prognosis and treatment\", section on 'Plasma biomarkers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic testing is not recommended in the routine evaluation of patients with AD. Genotyping with apolipoprotein E adds marginally to the predictive value of clinical criteria for AD and may stratify risk of conversion of amnesic MCI to AD, but both false positives and negatives occur [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/171,172\">",
"     171,172",
"    </a>",
"    ]. Genetic testing for presenilin-1 mutations is commercially available, but should be reserved for cases in which presenile dementia occurs in the setting of a positive family history; this should not be performed in asymptomatic individuals without appropriate professional genetic counseling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32089?source=see_link&amp;anchor=H899448#H899448\">",
"     \"Genetics of Alzheimer disease\", section on 'Apolipoprotein E'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Role of neuropsychological testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formal neuropsychological assessment can be helpful in the evaluation of individuals with cognitive impairment and dementia. Cognitive testing under standardized conditions using demographically appropriate norms is more sensitive to the presence of impairments, especially impairments of executive function. Neuropsychological assessment can establish a baseline in order to follow the patient over time. Neuropsychological assessment can also help differentiate between dementia and depression. Finally, neuropsychological consultation can assess competencies and guide recommendations pertaining to driving, financial decisions, and need for increasing supervision. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4552?source=see_link\">",
"     \"Safety and societal issues related to dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While different causes of dementia can preferentially affect different cognitive domains, neuropsychological testing has limited utility for differentiating among causes of dementia as there is substantial overlap in test performance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/33/27162/abstract/173\">",
"     173",
"    </a>",
"    ]. AD is characteristically associated with abnormalities in any or all cognitive domains, but absence of recent memory impairment should raise the suspicion of another diagnosis. The salient neuropsychological test features of other neurodegenerative dementias are discussed in individual topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=see_link\">",
"       \"Patient information: Dementia (including Alzheimer disease) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/22/32098?source=see_link\">",
"       \"Patient information: Tips for caregivers of people with Alzheimer disease (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/3/31793?source=see_link\">",
"       \"Patient information: Evaluating memory and thinking problems (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=see_link\">",
"       \"Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alzheimer disease (AD) is a neurodegenerative condition of uncertain etiology. It is the most common cause of dementia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AD is a disease of older age. Diagnosis before age 60 years is exceptional. The incidence increases exponentially with age. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Demographic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cognitive deficits in AD appear and progress insidiously. Memory impairment, specifically loss of memory of recent events, is an essential feature of AD and is usually its first manifestation. Deficits in other cognitive domains may appear with or after the development of memory impairment. Language function and visuospatial skills tend to be affected relatively early, while deficits in executive function and behavioral symptoms often manifest later in the disease course. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuropsychiatric and behavioral symptoms are common in middle and late stages of AD. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Neuropsychiatric symptoms'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link\">",
"       \"Treatment of behavioral symptoms related to dementia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Noncognitive neurologic deficits (pyramidal and extrapyramidal motor signs, myoclonus, and seizures) can occur in late stages of AD but are uncommon in early and middle stages. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Other neurologic deficits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atypical presentations of AD have been described. These include a visual variant (posterior cortical atrophy) and primary progressive aphasia. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Atypical presentations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AD is inexorably progressive, but the rate of progression can vary. The average life expectancy has been reported to be between three and eight years. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of AD is made by clinical assessment. Diagnostic tests (laboratories and neuroimaging) are performed primarily to exclude other diagnoses. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/1\">",
"      Ballard C, Gauthier S, Corbett A, et al. Alzheimer's disease. Lancet 2011; 377:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/2\">",
"      Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/3\">",
"      Fratiglioni L, Viitanen M, von Strauss E, et al. Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm. Neurology 1997; 48:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/4\">",
"      Schupf N, Kapell D, Nightingale B, et al. Earlier onset of Alzheimer's disease in men with Down syndrome. Neurology 1998; 50:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/5\">",
"      Markowitsch HJ, Staniloiu A. Amnesic disorders. Lancet 2012; 380:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/6\">",
"      SCOVILLE WB, MILNER B. Loss of recent memory after bilateral hippocampal lesions. J Neurol Neurosurg Psychiatry 1957; 20:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/7\">",
"      Zola-Morgan S, Squire LR, Amaral DG. Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus. J Neurosci 1986; 6:2950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/8\">",
"      Peters F, Collette F, Degueldre C, et al. The neural correlates of verbal short-term memory in Alzheimer's disease: an fMRI study. Brain 2009; 132:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/9\">",
"      Wagner M, Wolf S, Reischies FM, et al. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology 2012; 78:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/10\">",
"      Ahmed S, Mitchell J, Arnold R, et al. Memory complaints in mild cognitive impairment, worried well, and semantic dementia patients. Alzheimer Dis Assoc Disord 2008; 22:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/11\">",
"      Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/12\">",
"      Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study. Neurology 1996; 46:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/13\">",
"      Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/14\">",
"      Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004; 55:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/15\">",
"      Cerhan JH, Ivnik RJ, Smith GE, et al. Diagnostic utility of letter fluency, category fluency, and fluency difference scores in Alzheimer's disease. Clin Neuropsychol 2002; 16:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/16\">",
"      Canning SJ, Leach L, Stuss D, et al. Diagnostic utility of abbreviated fluency measures in Alzheimer disease and vascular dementia. Neurology 2004; 62:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/17\">",
"      Marczinski CA, Kertesz A. Category and letter fluency in semantic dementia, primary progressive aphasia, and Alzheimer's disease. Brain Lang 2006; 97:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/18\">",
"      Mendez MF, Mendez MA, Martin R, et al. Complex visual disturbances in Alzheimer's disease. Neurology 1990; 40:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/19\">",
"      Gu&eacute;rin F, Belleville S, Ska B. Characterization of visuoconstructional disabilities in patients with probable dementia of Alzheimer's type. J Clin Exp Neuropsychol 2002; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/20\">",
"      Hamilton L, Fay S, Rockwood K. Misplacing objects in mild to moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial. J Neurol Neurosurg Psychiatry 2009; 80:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/21\">",
"      Meguro K, Shimada M, Someya K, et al. Hemispatial visual-searching impairment correlated with decreased contralateral parietal blood flow in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/22\">",
"      Mendez MF, Cherrier MM, Cymerman JS. Hemispatial neglect on visual search tasks in Alzheimer's disease. Neuropsychiatry Neuropsychol Behav Neurol 1997; 10:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/23\">",
"      Shulman KI. Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry 2000; 15:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/24\">",
"      Harwood DG, Sultzer DL, Feil D, et al. Frontal lobe hypometabolism and impaired insight in Alzheimer disease. Am J Geriatr Psychiatry 2005; 13:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/25\">",
"      Barrett AM, Eslinger PJ, Ballentine NH, Heilman KM. Unawareness of cognitive deficit (cognitive anosognosia) in probable AD and control subjects. Neurology 2005; 64:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/26\">",
"      McDaniel KD, Edland SD, Heyman A. Relationship between level of insight and severity of dementia in Alzheimer disease. CERAD Clinical Investigators. Consortium to Establish a Registry for Alzheimer's Disease. Alzheimer Dis Assoc Disord 1995; 9:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/27\">",
"      Harwood DG, Sultzer DL, Wheatley MV. Impaired insight in Alzheimer disease: association with cognitive deficits, psychiatric symptoms, and behavioral disturbances. Neuropsychiatry Neuropsychol Behav Neurol 2000; 13:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/28\">",
"      Mizrahi R, Starkstein SE, Jorge R, Robinson RG. Phenomenology and clinical correlates of delusions in Alzheimer disease. Am J Geriatr Psychiatry 2006; 14:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/29\">",
"      Parakh R, Roy E, Koo E, Black S. Pantomime and imitation of limb gestures in relation to the severity of Alzheimer's disease. Brain Cogn 2004; 55:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/30\">",
"      Kato M, Meguro K, Sato M, et al. Ideomotor apraxia in patients with Alzheimer disease: why do they use their body parts as objects? Neuropsychiatry Neuropsychol Behav Neurol 2001; 14:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/31\">",
"      Giannakopoulos P, Duc M, Gold G, et al. Pathologic correlates of apraxia in Alzheimer disease. Arch Neurol 1998; 55:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/32\">",
"      Sarazin M, Stern Y, Berr C, et al. Neuropsychological predictors of dependency in patients with Alzheimer disease. Neurology 2005; 64:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/33\">",
"      Stokholm J, Vogel A, Gade A, Waldemar G. Heterogeneity in executive impairment in patients with very mild Alzheimer's disease. Dement Geriatr Cogn Disord 2006; 22:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/34\">",
"      Portet F, Scarmeas N, Cosentino S, et al. Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study. Arch Neurol 2009; 66:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/35\">",
"      McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/36\">",
"      Hauser WA, Morris ML, Heston LL, Anderson VE. Seizures and myoclonus in patients with Alzheimer's disease. Neurology 1986; 36:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/37\">",
"      McAreavey MJ, Ballinger BR, Fenton GW. Epileptic seizures in elderly patients with dementia. Epilepsia 1992; 33:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/38\">",
"      Romanelli MF, Morris JC, Ashkin K, Coben LA. Advanced Alzheimer's disease is a risk factor for late-onset seizures. Arch Neurol 1990; 47:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/39\">",
"      Scarmeas N, Honig LS, Choi H, et al. Seizures in Alzheimer disease: who, when, and how common? Arch Neurol 2009; 66:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/40\">",
"      Irizarry MC, Jin S, He F, et al. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol 2012; 69:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/41\">",
"      Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 2000; 123 Pt 3:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/42\">",
"      Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer's disease. Brain 2007; 130:2636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/43\">",
"      Harasty JA, Halliday GM, Xuereb J, et al. Cortical degeneration associated with phonologic and semantic language impairments in AD. Neurology 2001; 56:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/44\">",
"      Ng SY, Villemagne VL, Masters CL, Rowe CC. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. Arch Neurol 2007; 64:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/45\">",
"      Bokde AL, Pietrini P, Ib&aacute;&ntilde;ez V, et al. The effect of brain atrophy on cerebral hypometabolism in the visual variant of Alzheimer disease. Arch Neurol 2001; 58:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/46\">",
"      Whitwell JL, Dickson DW, Murray ME, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurol 2012; 11:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/47\">",
"      Ridgway GR, Lehmann M, Barnes J, et al. Early-onset Alzheimer disease clinical variants: multivariate analyses of cortical thickness. Neurology 2012; 79:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/48\">",
"      Balasa M, Gelpi E, Antonell A, et al. Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology 2011; 76:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/49\">",
"      van der Flier WM, Pijnenburg YA, Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE 4 allele. Lancet Neurol 2011; 10:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/50\">",
"      Cogan DG. Visual disturbances with focal progressive dementing disease. Am J Ophthalmol 1985; 100:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/51\">",
"      Hof PR, Bouras C, Constantinidis J, Morrison JH. Selective disconnection of specific visual association pathways in cases of Alzheimer's disease presenting with Balint's syndrome. J Neuropathol Exp Neurol 1990; 49:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/52\">",
"      Levine DN, Lee JM, Fisher CM. The visual variant of Alzheimer's disease: a clinicopathologic case study. Neurology 1993; 43:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/53\">",
"      Renner JA, Burns JM, Hou CE, et al. Progressive posterior cortical dysfunction: a clinicopathologic series. Neurology 2004; 63:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/54\">",
"      Andrade K, Kas A, Valabr&egrave;gue R, et al. Visuospatial deficits in posterior cortical atrophy: structural and functional correlates. J Neurol Neurosurg Psychiatry 2012; 83:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/55\">",
"      Pelak VS, Smyth SF, Boyer PJ, Filley CM. Computerized visual field defects in posterior cortical atrophy. Neurology 2011; 77:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/56\">",
"      Migliaccio R, Agosta F, Rascovsky K, et al. Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology 2009; 73:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/57\">",
"      Tang-Wai DF, Graff-Radford NR, Boeve BF, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004; 63:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/58\">",
"      Crutch SJ, Lehmann M, Schott JM, et al. Posterior cortical atrophy. Lancet Neurol 2012; 11:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/59\">",
"      Whitwell JL, Jack CR Jr, Kantarci K, et al. Imaging correlates of posterior cortical atrophy. Neurobiol Aging 2007; 28:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/60\">",
"      Rosenbloom MH, Alkalay A, Agarwal N, et al. Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology 2011; 76:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/61\">",
"      Josephs KA, Whitwell JL, Duffy JR, et al. Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology 2008; 70:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/62\">",
"      Knibb JA, Xuereb JH, Patterson K, Hodges JR. Clinical and pathological characterization of progressive aphasia. Ann Neurol 2006; 59:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/63\">",
"      Mesulam M, Wicklund A, Johnson N, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 2008; 63:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/64\">",
"      Xiong L, Xuereb JH, Spillantini MG, et al. Clinical comparison of progressive aphasia associated with Alzheimer versus FTD-spectrum pathology. J Neurol Neurosurg Psychiatry 2011; 82:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/65\">",
"      Rabinovici GD, Jagust WJ, Furst AJ, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008; 64:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/66\">",
"      Deramecourt V, Lebert F, Debachy B, et al. Prediction of pathology in primary progressive language and speech disorders. Neurology 2010; 74:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/67\">",
"      Hu WT, McMillan C, Libon D, et al. Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia. Neurology 2010; 75:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/68\">",
"      Pereira JM, Williams GB, Acosta-Cabronero J, et al. Atrophy patterns in histologic vs clinical groupings of frontotemporal lobar degeneration. Neurology 2009; 72:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/69\">",
"      Ross SJ, Graham N, Stuart-Green L, et al. Progressive biparietal atrophy: an atypical presentation of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996; 61:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/70\">",
"      Dickerson BC, Wolk DA, Alzheimer's Disease Neuroimaging Initiative. Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics. J Neurol Neurosurg Psychiatry 2011; 82:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/71\">",
"      Forman MS, Farmer J, Johnson JK, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol 2006; 59:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/72\">",
"      Galasko D, Hansen LA, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994; 51:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/73\">",
"      Connor DJ, Salmon DP, Sandy TJ, et al. Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease. Arch Neurol 1998; 55:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/74\">",
"      Weiner MF, Hynan LS, Parikh B, et al. Can alzheimer's disease and dementias with Lewy bodies be distinguished clinically? J Geriatr Psychiatry Neurol 2003; 16:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/75\">",
"      Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003; 60:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/76\">",
"      Clark CM, Sheppard L, Fillenbaum GG, et al. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol 1999; 56:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/77\">",
"      Adak S, Illouz K, Gorman W, et al. Predicting the rate of cognitive decline in aging and early Alzheimer disease. Neurology 2004; 63:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/78\">",
"      Nourhash&eacute;mi F, Ousset PJ, Gillette-Guyonnet S, et al. A 2-year follow-up of 233 very mild (CDR 0.5) Alzheimer's disease patients (REAL.FR cohort). Int J Geriatr Psychiatry 2008; 23:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/79\">",
"      Han L, Cole M, Bellavance F, et al. Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis. Int Psychogeriatr 2000; 12:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/80\">",
"      Schmidt C, Wolff M, Weitz M, et al. Rapidly progressive Alzheimer disease. Arch Neurol 2011; 68:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/81\">",
"      Bernick C, Cummings J, Raman R, et al. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol 2012; 69:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/82\">",
"      Helzner EP, Scarmeas N, Cosentino S, et al. Survival in Alzheimer disease: a multiethnic, population-based study of incident cases. Neurology 2008; 71:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/83\">",
"      Larson EB, Shadlen MF, Wang L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 2004; 140:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/84\">",
"      Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001; 344:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/85\">",
"      Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/86\">",
"      Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997; 18:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/87\">",
"      Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/88\">",
"      Folstein MF, Folstein SE, McHugh PR. \"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/89\">",
"      Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 1992; 40:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/90\">",
"      Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993; 269:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/91\">",
"      McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/92\">",
"      M&ouml;ls&auml; PK, Palj&auml;rvi L, Rinne JO, et al. Validity of clinical diagnosis in dementia: a prospective clinicopathological study. J Neurol Neurosurg Psychiatry 1985; 48:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/93\">",
"      Gearing M, Mirra SS, Hedreen JC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology 1995; 45:461.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and statistical manual of mental disorders (IV-TR). 4th edition-text revised. Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/95\">",
"      Phung TK, Andersen BB, H&oslash;gh P, et al. Validity of dementia diagnoses in the Danish hospital registers. Dement Geriatr Cogn Disord 2007; 24:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/96\">",
"      Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/97\">",
"      van de Pol LA, Hensel A, Barkhof F, et al. Hippocampal atrophy in Alzheimer disease: age matters. Neurology 2006; 66:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/98\">",
"      Barkhof F, Polvikoski TM, van Straaten EC, et al. The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology 2007; 69:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/99\">",
"      Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008; 71:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/100\">",
"      Kantarci K, Avula R, Senjem ML, et al. Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI. Neurology 2010; 74:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/101\">",
"      Raji CA, Lopez OL, Kuller LH, et al. Age, Alzheimer disease, and brain structure. Neurology 2009; 73:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/102\">",
"      Wahlund LO, Almkvist O, Blennow K, et al. Evidence-based evaluation of magnetic resonance imaging as a diagnostic tool in dementia workup. Top Magn Reson Imaging 2005; 16:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/103\">",
"      Dickerson BC, Wolk DA, Alzheimer's Disease Neuroimaging Initiative. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology 2012; 78:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/104\">",
"      Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/105\">",
"      Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 2001; 286:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/106\">",
"      Powers WJ, Perlmutter JS, Videen TO, et al. Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer's disease. Neurology 1992; 42:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/107\">",
"      Duara R, Grady C, Haxby J, et al. Positron emission tomography in Alzheimer's disease. Neurology 1986; 36:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/108\">",
"      O'Brien JL, O'Keefe KM, LaViolette PS, et al. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology 2010; 74:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/109\">",
"      Hu WT, Wang Z, Lee VM, et al. Distinct cerebral perfusion patterns in FTLD and AD. Neurology 2010; 75:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/110\">",
"      Pickut BA, Saerens J, Mari&euml;n P, et al. Discriminative use of SPECT in frontal lobe-type dementia versus (senile) dementia of the Alzheimer's type. J Nucl Med 1997; 38:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/111\">",
"      Ishii K, Sakamoto S, Sasaki M, et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med 1998; 39:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/112\">",
"      Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007; 130:2616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/113\">",
"      Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011; 77:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/114\">",
"      Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 2004; 3:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/115\">",
"      Rabinovici GD, Furst AJ, O'Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007; 68:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/116\">",
"      Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007; 68:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/117\">",
"      Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/118\">",
"      Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008; 7:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/119\">",
"      Small GW, Bookheimer SY, Thompson PM, et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol 2008; 7:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/120\">",
"      Ances BM, Christensen JJ, Teshome M, et al. Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study. Neurology 2010; 75:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/121\">",
"      Roe CM, Mintun MA, Ghoshal N, et al. Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept. Neurology 2010; 75:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/122\">",
"      Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010; 68:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/123\">",
"      Tolboom N, van der Flier WM, Boverhoff J, et al. Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. J Neurol Neurosurg Psychiatry 2010; 81:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/124\">",
"      Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/125\">",
"      Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-&beta; PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011; 10:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/126\">",
"      Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 2011; 68:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/127\">",
"      Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011; 68:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/128\">",
"      Wolk DA, Zhang Z, Boudhar S, et al. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry 2012; 83:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/129\">",
"      Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-&beta; plaques: a prospective cohort study. Lancet Neurol 2012; 11:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/130\">",
"      Doraiswamy PM, Sperling RA, Coleman RE, et al. Amyloid-&beta; assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012; 79:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/131\">",
"      Lim YY, Ellis KA, Pietrzak RH, et al. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology 2012; 79:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/132\">",
"      Niedowicz DM, Beckett TL, Matveev S, et al. Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease. Ann Neurol 2012; 72:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/133\">",
"      Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/134\">",
"      Yang L, Rieves D, Ganley C. Brain amyloid imaging--FDA approval of florbetapir F18 injection. N Engl J Med 2012; 367:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/135\">",
"      Silverman DH, Cummings JL, Small GW, et al. Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol Imaging Biol 2002; 4:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/136\">",
"      Jagust W, Reed B, Mungas D, et al. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007; 69:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/137\">",
"      Galasko D, Clark C, Chang L, et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology 1997; 48:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/138\">",
"      Kahle PJ, Jakowec M, Teipel SJ, et al. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology 2000; 54:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/139\">",
"      Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003; 289:2094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/140\">",
"      Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003; 60:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/141\">",
"      Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001; 58:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/142\">",
"      Maddalena A, Papassotiropoulos A, M&uuml;ller-Tillmanns B, et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch Neurol 2003; 60:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/143\">",
"      G&oacute;mez-Tortosa E, Gonzalo I, Fanjul S, et al. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol 2003; 60:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/144\">",
"      Fagan AM, Roe CM, Xiong C, et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/145\">",
"      Graff-Radford NR, Crook JE, Lucas J, et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007; 64:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/146\">",
"      Gustafson DR, Skoog I, Rosengren L, et al. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 2007; 78:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/147\">",
"      Bian H, Van Swieten JC, Leight S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 2008; 70:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/148\">",
"      Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008; 71:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/149\">",
"      Kester MI, van der Vlies AE, Blankenstein MA, et al. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 2009; 73:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/150\">",
"      Wallin AK, Blennow K, Zetterberg H, et al. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 2010; 74:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/151\">",
"      De Meyer G, Shapiro F, Vanderstichele H, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010; 67:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/152\">",
"      Yaffe K, Weston A, Graff-Radford NR, et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 2011; 305:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/153\">",
"      Gupta VB, Laws SM, Villemagne VL, et al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 2011; 76:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/154\">",
"      de Souza LC, Lamari F, Belliard S, et al. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. J Neurol Neurosurg Psychiatry 2011; 82:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/155\">",
"      Tarawneh R, D'Angelo G, Macy E, et al. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol 2011; 70:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/156\">",
"      Schoonenboom NS, Reesink FE, Verwey NA, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012; 78:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/157\">",
"      Mattsson N, Ros&eacute;n E, Hansson O, et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 2012; 78:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/158\">",
"      Watabe-Rudolph M, Song Z, Lausser L, et al. Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. Neurology 2012; 78:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/159\">",
"      Tarawneh R, Lee JM, Ladenson JH, et al. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 2012; 78:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/160\">",
"      Kas A, Uspenskaya O, Lamari F, et al. Distinct brain perfusion pattern associated with CSF biomarkers profile in primary progressive aphasia. J Neurol Neurosurg Psychiatry 2012; 83:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/161\">",
"      Hu WT, Holtzman DM, Fagan AM, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 2012; 79:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/162\">",
"      Irwin DJ, McMillan CT, Toledo JB, et al. Comparison of cerebrospinal fluid levels of tau and A&beta; 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch Neurol 2012; 69:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/163\">",
"      Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/164\">",
"      Soares HD, Potter WZ, Pickering E, et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol 2012; 69:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/165\">",
"      Doecke JD, Laws SM, Faux NG, et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 2012; 69:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/166\">",
"      Hall S, &Ouml;hrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012; 69:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/167\">",
"      Galasko D. Cerebrospinal fluid biomarkers in Alzheimer disease: a fractional improvement? Arch Neurol 2003; 60:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/168\">",
"      Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007; 68:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/169\">",
"      Bouwman FH, van der Flier WM, Schoonenboom NS, et al. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 2007; 69:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/170\">",
"      Sonnen JA, Montine KS, Quinn JF, et al. Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol 2008; 7:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/171\">",
"      Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 1998; 338:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/172\">",
"      Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/33/27162/abstract/173\">",
"      Hutchinson AD, Mathias JL. Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic review. J Neurol Neurosurg Psychiatry 2007; 78:917.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5071 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-7AD06D259D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_33_27162=[""].join("\n");
var outline_f26_33_27162=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEMOGRAPHIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Memory impairment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Amnestic mild cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other aspects of cognitive decline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Language",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Visuospatial skills",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Insight",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Apraxia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Executive function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Neuropsychiatric symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other neurologic deficits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Atypical presentations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Posterior cortical atrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Primary progressive aphasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Biparietal syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Mixed dementias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Clinical assessments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Clinical criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Role of neuropsychological testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5071\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5071|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/0/2\" title=\"table 1\">",
"      Clinical dementia rating",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20041?source=related_link\">",
"      Approach to the patient with aphasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1913?source=related_link\">",
"      Cholinesterase inhibitors in the treatment of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=related_link\">",
"      Clinical features and diagnosis of dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of vascular dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=related_link\">",
"      Frontotemporal dementia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32089?source=related_link\">",
"      Genetics of Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27161?source=related_link\">",
"      Mild cognitive impairment: Epidemiology, pathology, and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26138?source=related_link\">",
"      Mild cognitive impairment: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/3/31793?source=related_link\">",
"      Patient information: Evaluating memory and thinking problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/22/32098?source=related_link\">",
"      Patient information: Tips for caregivers of people with Alzheimer disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=related_link\">",
"      Risk factors for dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4552?source=related_link\">",
"      Safety and societal issues related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40841?source=related_link\">",
"      Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23303?source=related_link\">",
"      The mental status examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=related_link\">",
"      Treatment of dementia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_33_27163="Kings College criteria";
var content_f26_33_27163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    King's College Hospital criteria for liver transplantation in acute liver failure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Acetaminophen-induced disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Arterial pH &lt;7.3 (irrespective of the grade of encephalopathy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Grade III or IV encephalopathy AND",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prothrombin time &gt;100 seconds AND",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serum creatinine &gt;3.4mg/dL (301 &micro;mol/L)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       All other causes of acute liver failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prothrombin time &gt;100 seconds (irrespective of the grade of encephalopathy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any",
"       <strong>",
"        three",
"       </strong>",
"       of the following variables (irrespective of the grade of encephalopathy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Age &lt;10 years or &gt;40 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Etiology: non-A, non-B hepatitis, halothane hepatitis, idiosyncratic drug reactions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Duration of jaundice before onset of encephalopathy &gt;7 days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Prothrombin time &gt;50 seconds",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Serum bilirubin &gt;18 mg/dL (308 &micro;mol/L)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: O'Grady JG, Alexander GJM, Hayllar KM, et al. Gastroenterology 1989; 97:439.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_33_27163=[""].join("\n");
var outline_f26_33_27163=null;
var title_f26_33_27164="Eval isolated transaminitis";
var content_f26_33_27164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of isolated mild chronic elevation of serum aminotransferases*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Step 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Review possible link to medications, herbal therapies, or recreational drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Screen for alcohol abuse (screening instruments, AST/ALT ratio &gt;2:1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain serology for hepatitis B and C (HBsAg, anti-HBs, anti-HBc, anti-HCV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Screen for hemochromatosis (Fe/TIBC &gt;45 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate for fatty liver (AST/ALT usually &lt;1, obtain RUQ ultrasonography)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Step 2: If the above is unrevealing confirm that source is hepatic and consider proceeding to Step 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exclude muscle disorders (obtain creatinine kinase or aldolase)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain thyroid function tests (TSH if hypothyroidism is suspected otherwise obtain serum TSH, free T4, and T3 concentrations)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider celiac disease (especially in patients with a history of diarrhea or unexplained iron deficiency: serum antiendomysial IgA or anti tissue transglutaminase antibodies are reasonable screening tests)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider adrenal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Step 3: Consider less common causes of liver disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider autoimmune hepatitis particularly in women and those with a history of other autoimmune disorders (check serum protein electrophoresis; obtain ANA and ASMA if positive)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider Wilson disease in those &lt;40 years age (check serum ceruloplasmin, evaluate for Kayser Fleischer rings)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider alpha-1 antitrypsin deficiency especially in patients with a history of emphysema out of proportion to their age or smoking history (obtain alpha-1 antitrypsin phenotype)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Step 4: Obtain a liver biopsy or observe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Observe if ALT and AST are less than twofold elevated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Otherwise consider a liver biopsy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ALT: alanine aminotransferase; ANA: antinuclear antibodies; ASMA: anti-smooth muscle antibodies; AST: aspartate aminotransferase; anti-HBs: antibody to hepatitis B surface antigen; anti-HBc: antibody to hepatitis B core antigen; anti-HCV: antibody to hepatitis C virus; HBsAg: hepatitis B surface antigen; Ig: immunoglobulin; RUQ: right upper quadrant; TIBC: total iron binding capacity; TSH: thyroid-stimulating hormone.",
"     <br/>",
"     * Mild is defined as &lt;250 unit/L; chronic is defined as more than six months.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_33_27164=[""].join("\n");
var outline_f26_33_27164=null;
var title_f26_33_27165="High fiber diet 2 PI";
var content_f26_33_27165=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F67749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F67749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    High-fiber diet guidelines (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       High-fiber diet guidelines from Texas Children's Hospital",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\">",
"       Read labels on foods, and look for 3 or more grams of fiber per serving. Eat 3 or more servings each day of breads and cereals made from whole grains and bran. Eat 5 or more servings each day of fruits and vegetables, including beans. It is important to increase water in the diet when you increase fiber.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\">",
"       Meat, poultry, fish, milk, milk products, and fats such as oil, margarine, and salad dressings do not normally have fiber, but it is important to include these in your child's diet to provide a complete balance of foods.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       High-fiber dry cereals",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\">",
"       One serving equals 1/2 cup.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Cereal",
"      </td>",
"      <td class=\"subtitle2\">",
"       Fiber, grams",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fiber One",
"      </td>",
"      <td>",
"       13",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       100 percent Bran",
"      </td>",
"      <td>",
"       12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       All Bran",
"      </td>",
"      <td>",
"       12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bran Buds",
"      </td>",
"      <td>",
"       12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Kellogg's Complete Bran Flakes",
"      </td>",
"      <td>",
"       5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Grape Nuts",
"      </td>",
"      <td>",
"       5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Raisin Bran",
"      </td>",
"      <td>",
"       3 to 5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cracklin' Oat Bran",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       100 percent Whole Grain Wheat Chex",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fruit and Fibre",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Great Grains",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Frosted Mini Wheats",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Kellogg's Low-Fat Granola",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cheerios",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Wheaties",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       High-fiber vegetables (cooked unless indicated)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\">",
"       One serving of vegetables is 1/2 to 1 cup.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Vegetable",
"      </td>",
"      <td class=\"subtitle2\">",
"       Fiber, grams",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pinto, kidney, black, lima beans (1/2 cup)",
"      </td>",
"      <td>",
"       4 to 7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sweet potato (1 medium)",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lentils (1/2 cup)",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Jicama (1/2 raw)",
"      </td>",
"      <td>",
"       3 to 4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Baked potato with skin (medium)",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Corn (1/2 cup)",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Peas (1/2 cup)",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Broccoli (1/2 cup)",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cabbage (1/2 cup)",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Spinach (1/2 cup)",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cauliflower (3/4 cup)",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Carrots (1 medium raw or 1/2 cup cooked)",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       High-fiber fruits",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"2\">",
"       One serving of fruit is usually one piece.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Fruit",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"3\">",
"       Fiber, grams",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pear",
"      </td>",
"      <td colspan=\"3\">",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Strawberries (one cup)",
"      </td>",
"      <td colspan=\"3\">",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Apple (with skin)",
"      </td>",
"      <td colspan=\"3\">",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dried fruits like raisins (3 tablespoons)",
"      </td>",
"      <td colspan=\"3\">",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Papaya",
"      </td>",
"      <td colspan=\"3\">",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Peach (fresh)",
"      </td>",
"      <td colspan=\"3\">",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Plums (2)",
"      </td>",
"      <td colspan=\"3\">",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mango",
"      </td>",
"      <td colspan=\"3\">",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nectarine",
"      </td>",
"      <td colspan=\"3\">",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Avocado (1/2 medium)",
"      </td>",
"      <td colspan=\"3\">",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tomato (1 medium)",
"      </td>",
"      <td colspan=\"3\">",
"       2",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    These guidelines are continued.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_33_27165=[""].join("\n");
var outline_f26_33_27165=null;
var title_f26_33_27166="Pneumonia hospitalization children";
var content_f26_33_27166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Annual all-cause pneumonia hospitalization rates* among children aged &lt;2 years and 2-4 years - Nationwide Inpatient Sample, United States, 1997-2006",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 386px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Per 1000 population.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      95% confidence interval.",
"      <br>",
"       &Delta; 7-valent pneumococcal conjugate vaccine licensed in February 2000.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Centers for Disease Control and Prevention. Pneumonia Hospitalizations Among Young Children Before and After Introduction of Pneumococcal Conjugate Vaccine - United States, 1997-2006. MMWR 2009; 58:3.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_33_27166=[""].join("\n");
var outline_f26_33_27166=null;
var title_f26_33_27167="Charcot foot PI";
var content_f26_33_27167=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F50500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F50500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Charcot arthropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This person with diabetes has joint and bone damage called Charcot arthropathy. The arch of the person's foot has collapsed and been replaced by a bony growth (see arrow). Several factors contribute to this painless condition, including the loss of muscle, decreased sensation, and inappropriate weight distribution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David McCulloch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_33_27167=[""].join("\n");
var outline_f26_33_27167=null;
